

Kaj Blennow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3300767/publications.pdf>

Version: 2024-02-01

1,399
papers

119,220
citations

168

155
h-index

270

297
g-index

1519
all docs

1519
docs citations

1519
times ranked

57845
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non- β -Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820. | 0.8 | 4 |
| 2 | Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806. | 0.8 | 24 |
| 3 | Genotypic effects of ϵ -APOE ϵ -4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760. | 2.9 | 5 |
| 4 | Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers. <i>Translational Stroke Research</i> , 2022, 13, 65-76. | 4.2 | 17 |
| 5 | Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 65-76. | 0.8 | 18 |
| 6 | Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190. | 0.8 | 5 |
| 7 | Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 125-132. | 1.3 | 17 |
| 8 | State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177. | 0.8 | 33 |
| 9 | Dynamics of Selected Biomarkers in Cerebrospinal Fluid During Complex Endovascular Aortic Repair – A Pilot Study. <i>Annals of Vascular Surgery</i> , 2022, 78, 141-151. | 0.9 | 1 |
| 10 | Cardiac troponin T is elevated and increases longitudinally in ALS patients. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 58-65. | 1.7 | 8 |
| 11 | Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma $A\beta_{42}/A\beta_{40}$ and $p\tau$. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293. | 0.8 | 72 |
| 12 | Cohort Analysis of the Association of Delirium Severity With Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 494-501. | 3.6 | 20 |
| 13 | Preclinical <i>in vivo</i> longitudinal assessment of KC207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801. | 4.3 | 8 |
| 14 | Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 872-884. | 3.0 | 10 |
| 15 | Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. <i>British Journal of Haematology</i> , 2022, 196, 248-254. | 2.5 | 9 |
| 16 | Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 875-887. | 0.8 | 22 |
| 17 | Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022, 36, 75-82. | 2.2 | 7 |
| 18 | Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154. | 0.8 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial. <i>Medical Gas Research</i> , 2022, 12, 10. | 2.3 | 8 |
| 20 | Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. <i>European Journal of Nutrition</i> , 2022, 61, 871-884. | 3.9 | 15 |
| 21 | Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. <i>Journal of Affective Disorders</i> , 2022, 297, 623-633. | 4.1 | 13 |
| 22 | Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage. <i>Stroke</i> , 2022, 53, 808-816. | 2.0 | 0 |
| 23 | Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305. | 2.3 | 10 |
| 24 | The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. <i>Journal of Neuroradiology</i> , 2022, 49, 421-427. | 1.1 | 13 |
| 25 | Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32. | 9.0 | 38 |
| 26 | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66. | 10.2 | 203 |
| 27 | Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219. | 2.3 | 44 |
| 28 | Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. <i>Journal of Neurology</i> , 2022, 269, 3064-3074. | 3.6 | 8 |
| 29 | Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2022, 18, 1484-1497. | 0.8 | 84 |
| 30 | Gfap and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. <i>Resuscitation</i> , 2022, 170, 141-149. | 3.0 | 13 |
| 31 | Plasma p-tau ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 1523-1536. | 0.8 | 18 |
| 32 | Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. <i>EBioMedicine</i> , 2022, 75, 103793. | 6.1 | 4 |
| 33 | N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848. | 7.6 | 20 |
| 34 | Plasma p-tau ₂₃₁ , p-tau ₁₈₁ , ¹⁸ F-PET Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560. | 5.3 | 42 |
| 35 | Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. <i>Communications Medicine</i> , 2022, 2, . | 4.2 | 2 |
| 36 | Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. <i>Pain Reports</i> , 2022, 7, e988. | 2.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. <i>Alzheimer's and Dementia</i> , 2022, , . | 0.8 | 3 |
| 38 | Association of APOE ϵ 4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1309-1320. | 2.6 | 11 |
| 39 | Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233. | 0.8 | 24 |
| 40 | Crosswalk study on blood collectionâ€”tube types for Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12266. | 2.4 | 8 |
| 41 | Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 11. | 5.0 | 18 |
| 42 | Amyloid processing in <scp>COVID</scp>â€”associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157. | 3.9 | 35 |
| 43 | Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 447-453. | 1.6 | 14 |
| 44 | Slowing gait speed precedes cognitive decline by several years. <i>Alzheimer's and Dementia</i> , 2022, 18, 1667-1676. | 0.8 | 24 |
| 45 | ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease â€” Study Protocol and Baseline Characteristics. <i>Frontiers in Neurology</i> , 2022, 13, 826423. | 2.4 | 7 |
| 46 | Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836. | 6.1 | 65 |
| 47 | The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26. | 6.2 | 49 |
| 48 | Postoperative delirium and changes in the bloodâ€”brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. <i>British Journal of Anaesthesia</i> , 2022, 129, 219-230. | 3.4 | 55 |
| 49 | Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837. | 6.1 | 34 |
| 50 | Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. <i>Emergency Medicine Journal</i> , 2022, 39, 206-212. | 1.0 | 7 |
| 51 | Plasma and CSF NFL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€”based sample of 70â€”yearâ€”olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12295. | 2.4 | 11 |
| 52 | Bloodâ€”brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor proteinâ€” β 2 in patients with subcortical smallâ€”vessel disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12296. | 2.4 | 5 |
| 53 | Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 15. | 5.0 | 7 |
| 54 | Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia. <i>Cells</i> , 2022, 11, 789. | 4.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626. | 0.8 | 22 |
| 56 | Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237. | 2.8 | 7 |
| 57 | Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1721-1734. | 2.6 | 3 |
| 58 | Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis. <i>Alzheimer's and Dementia</i> , 2022, , . | 0.8 | 3 |
| 59 | Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503. | 7.7 | 89 |
| 60 | Exploring common genetic contributors to neuroprotection from amyloid pathology. <i>Brain Communications</i> , 2022, 4, fca066. | 3.3 | 10 |
| 61 | Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. <i>Brain Communications</i> , 2022, 4, fca040. | 3.3 | 8 |
| 62 | Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. <i>Brain Injury</i> , 2022, 36, 800-809. | 1.2 | 7 |
| 63 | Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257. | 10.2 | 210 |
| 64 | Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27. | 10.8 | 30 |
| 65 | Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 46. | 6.2 | 17 |
| 66 | Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651. | 3.4 | 20 |
| 67 | Age, sex and APOE-ε4 modify the balance between soluble and fibrillar Aβ-amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018. | 7.9 | 9 |
| 68 | Cerebral biomarkers in neurologic complications of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 298.e1-298.e10. | 1.3 | 7 |
| 69 | Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. <i>Frontiers in Neurology</i> , 2022, 13, 839307. | 2.4 | 8 |
| 70 | Development of Fluid Biomarkers for Alzheimer's Disease. , 2022, , 361-374. | | 0 |
| 71 | Post-acute blood biomarkers and disease progression in traumatic brain injury. <i>Brain</i> , 2022, 145, 2064-2076. | 7.6 | 37 |
| 72 | Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease. <i>Translational Psychiatry</i> , 2022, 12, 151. | 4.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341. | 10.2 | 72 |
| 74 | Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnesic Subtypes of Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 755454. | 3.4 | 2 |
| 75 | Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879. | 0.8 | 26 |
| 76 | Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. <i>Journal of Neurochemistry</i> , 2022, 160, 482-498. | 3.9 | 17 |
| 77 | β -Secretase modulators show selectivity for β -Secretase-mediated amyloid precursor protein intramembrane processing. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 880-892. | 3.6 | 4 |
| 78 | Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. <i>Brain</i> , 2022, 145, 2149-2160. | 7.6 | 20 |
| 79 | Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. <i>Neurology</i> , 2022, 98, . | 1.1 | 7 |
| 80 | Effect of Race on Prediction of Brain Amyloidosis by Plasma $A\beta^{242}/A\beta^{240}$, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, . | 1.1 | 63 |
| 81 | Statistical Parametric Mapping in Amyloid Positron Emission Tomography. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 849932. | 3.4 | 4 |
| 82 | Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2022, 116, 80-91. | 3.1 | 5 |
| 83 | Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535. | 11.6 | 73 |
| 84 | Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis: a prospective follow-up study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1124-1132. | 2.3 | 3 |
| 85 | Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192. | 1.5 | 16 |
| 86 | Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557. | 7.6 | 15 |
| 87 | Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 882-887. | 3.7 | 5 |
| 88 | Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65. | 6.2 | 25 |
| 89 | Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103846. | 2.0 | 3 |
| 90 | Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. <i>Clinical Proteomics</i> , 2022, 19, 13. | 2.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418. | 10.1 | 99 |
| 92 | Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. <i>British Journal of Haematology</i> , 2022, , . | 2.5 | 7 |
| 93 | Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, . | 6.2 | 12 |
| 94 | Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298. | 2.5 | 9 |
| 95 | Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. <i>European Journal of Neurology</i> , 2022, 29, 2810-2822. | 3.3 | 20 |
| 96 | A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, . | 1.1 | 8 |
| 97 | Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. <i>Neurology</i> , 2022, 99, . | 1.1 | 10 |
| 98 | Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, . | 6.2 | 11 |
| 99 | Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1859-1870. | 3.0 | 14 |
| 100 | Reply to "Pathway for ascertaining the role of uric acid in neurodegenerative diseases," Roman Youssef. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, . | 2.4 | 0 |
| 101 | Investigating the use of plasma pTau181 in retired contact sports athletes. <i>Journal of Neurology</i> , 2022, 269, 5582-5595. | 3.6 | 4 |
| 102 | Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to β -amyloid positivity. <i>Sleep</i> , 2022, 45, . | 1.1 | 22 |
| 103 | Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, . | 3.7 | 5 |
| 104 | Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210981. | 1.9 | 2 |
| 105 | Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7182. | 4.1 | 3 |
| 106 | Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. <i>Brain Communications</i> , 2022, 4, . | 3.3 | 57 |
| 107 | Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's disease continuum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4567-4579. | 6.4 | 16 |
| 108 | Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1907-1915. | 4.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976. | 7.9 | 76 |
| 110 | Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. <i>Journal of Neurochemistry</i> , 2021, 159, 389-402. | 3.9 | 20 |
| 111 | Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. <i>Molecular Psychiatry</i> , 2021, 26, 5940-5954. | 7.9 | 56 |
| 112 | Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001. | 7.9 | 28 |
| 113 | Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2021, 26, 5766-5788. | 7.9 | 63 |
| 114 | CSF β -synuclein correlates with CSF neurogranin in late-life depression. <i>International Journal of Neuroscience</i> , 2021, 131, 357-361. | 1.6 | 10 |
| 115 | Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. <i>Resuscitation</i> , 2021, 158, 253-257. | 3.0 | 14 |
| 116 | Determining Amyloid- β Positivity Using 18 F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252. | 5.0 | 65 |
| 117 | Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. <i>Sleep</i> , 2021, 44, . | 1.1 | 22 |
| 118 | No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS) Tj ETQq0 0.0 BT / Overlock 10 T | 0.0 | 0 |
| 119 | Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. <i>European Journal of Neurology</i> , 2021, 28, 587-594. | 3.3 | 6 |
| 120 | Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. <i>British Journal of Anaesthesia</i> , 2021, 126, 467-476. | 3.4 | 17 |
| 121 | Molecular forms of neurogranin in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2021, 157, 816-833. | 3.9 | 6 |
| 122 | Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767. | 0.8 | 81 |
| 123 | Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123. | 11.6 | 94 |
| 124 | Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 259-265. | 3.7 | 25 |
| 125 | Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339. | 7.6 | 124 |
| 126 | Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324. | 7.6 | 123 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, 822-830. | 0.8 | 27 |
| 128 | Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. <i>British Journal of Anaesthesia</i> , 2021, 126, 458-466. | 3.4 | 75 |
| 129 | Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 229-235. | 1.1 | 11 |
| 130 | Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 729-741. | 2.6 | 10 |
| 131 | An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 431-445. | 0.8 | 80 |
| 132 | Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. <i>Clinica Chimica Acta</i> , 2021, 512, 74-83. | 1.1 | 8 |
| 133 | Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021, 28, 974-981. | 3.3 | 30 |
| 134 | A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 141, 217-233. | 7.7 | 33 |
| 135 | Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 303-312. | 2.1 | 9 |
| 136 | Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442. | 7.9 | 186 |
| 137 | Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2021, 268, 1385-1394. | 3.6 | 18 |
| 138 | 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 29-40. | 0.8 | 77 |
| 139 | Serum neuroproteins, near-infrared spectroscopy, and cognitive outcome after beach chair shoulder surgery: Observational cohort study analyses. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 26-33. | 1.6 | 5 |
| 140 | Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. <i>Intensive Care Medicine</i> , 2021, 47, 39-48. | 8.2 | 90 |
| 141 | Association of Early β -Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. <i>Neurology</i> , 2021, 96, e1608-e1619. | 1.1 | 30 |
| 142 | A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 983-990. | 3.6 | 18 |
| 143 | Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 225-235. | 2.6 | 4 |
| 144 | Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168. | 2.4 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12141. | 2.4 | 9 |
| 146 | Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12145. | 2.4 | 17 |
| 147 | The relationship between white matter microstructure and self-perceived cognitive decline. <i>NeuroImage: Clinical</i> , 2021, 32, 102794. | 2.7 | 9 |
| 148 | Measurement batch differences and between-batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12194. | 2.4 | 2 |
| 149 | Parkinson's disease with restless legs syndrome—an in vivo corneal confocal microscopy study. <i>Npj Parkinson's Disease</i> , 2021, 7, 4. | 5.3 | 10 |
| 150 | Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2021, 34, 1-10. | 1.7 | 7 |
| 151 | Plasma metabolomics of presymptomatic <i>PSEN1</i> H163Y mutation carriers: a pilot study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 579-591. | 3.7 | 0 |
| 152 | A Western-style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's disease—A population-based cross-sectional study among 70-year-olds. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12183. | 3.7 | 11 |
| 153 | Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i> , 2021, 28, 3324-3331. | 3.3 | 109 |
| 154 | Head-to-head comparison of amplified plasmonic exosome A β 42 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489. | 3.3 | 11 |
| 155 | Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17. | 6.2 | 35 |
| 156 | Plasma β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640. | 0.8 | 10 |
| 157 | Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021, 9, 19. | 5.2 | 17 |
| 158 | Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <i>Molecular Neurodegeneration</i> , 2021, 16, 10. | 10.8 | 101 |
| 159 | Detection of β -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008. | 3.3 | 51 |
| 160 | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38. | 6.2 | 12 |
| 161 | Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821. | 0.8 | 8 |
| 162 | Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1297-1305. | 2.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Plasma p-tau ₂₃₁ : a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724. | 7.7 | 285 |
| 164 | Signs of neuroaxonal injury in preeclampsia—A case control study. <i>PLoS ONE</i> , 2021, 16, e0246786. | 2.5 | 17 |
| 165 | Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. <i>Critical Care</i> , 2021, 25, 83. | 5.8 | 23 |
| 166 | Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 46. | 6.2 | 9 |
| 167 | Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 1212-1221. | 1.2 | 16 |
| 168 | Plasma p-tau ₁₈₁ to A β ₄₂ ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662. | 0.8 | 37 |
| 169 | Cerebral amyloid β ₂ load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800. | 0.8 | 14 |
| 170 | Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812. | 0.8 | 18 |
| 171 | Proteomic blood profiling in mild, severe and critical COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 6357. | 3.3 | 72 |
| 172 | 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2121-2139. | 6.4 | 43 |
| 173 | The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β ₂ and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582. | 0.8 | 51 |
| 174 | Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464. | 0.8 | 13 |
| 175 | Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal parenchymal integrity in healthy men. <i>Journal of Applied Physiology</i> , 2021, 130, 792-800. | 2.5 | 6 |
| 176 | Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 68. | 6.2 | 117 |
| 177 | The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156. | 6.4 | 83 |
| 178 | Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , 2021, 8, e000463. | 2.7 | 8 |
| 179 | Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3574-3583. | 3.6 | 56 |
| 180 | Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 65. | 6.2 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 64. | 6.2 | 6 |
| 182 | Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes. <i>PLoS ONE</i> , 2021, 16, e0247753. | 2.5 | 16 |
| 183 | Association of CSF proteins with tau and amyloid β^2 levels in asymptomatic 70-year-olds. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 54. | 6.2 | 9 |
| 184 | Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69. | 6.2 | 34 |
| 185 | Plasma amyloid- β^2 ratios in autosomal dominant Alzheimer's disease: the influence of genotype. <i>Brain</i> , 2021, 144, 2964-2970. | 7.6 | 16 |
| 186 | Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. <i>Journal of Neuroimmunology</i> , 2021, 353, 577493. | 2.3 | 4 |
| 187 | No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 800-804. | 2.6 | 2 |
| 188 | Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 86. | 6.2 | 19 |
| 189 | TREM2 expression in the brain and biological fluids in prion diseases. <i>Acta Neuropathologica</i> , 2021, 141, 841-859. | 7.7 | 18 |
| 190 | Synergistic Association between Plasma β^2 and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1376-1383. | 3.5 | 9 |
| 191 | Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204. | 0.8 | 44 |
| 192 | Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073. | 3.3 | 15 |
| 193 | Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396. | 9.0 | 146 |
| 194 | Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. <i>JAMA Network Open</i> , 2021, 4, e214138. | 5.9 | 15 |
| 195 | Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 791-798. | 3.4 | 15 |
| 196 | One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2021, 12, 643743. | 2.4 | 20 |
| 197 | Plasma neurofilament light chain levels predict improvement in late phase after stroke. <i>European Journal of Neurology</i> , 2021, 28, 2218-2228. | 3.3 | 10 |
| 198 | Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898. | 3.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Characterization of monomeric and soluble aggregated A β 2 in Down β ™s syndrome and Alzheimer β ™s disease brains. Neuroscience Letters, 2021, 754, 135894. | 2.1 | 9 |
| 200 | Effects of amyloid pathology and the APOE ϵ 4 allele on the association between cerebrospinal fluid A β 238 and A β 240 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12. | 3.1 | 7 |
| 201 | Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. Journal of Affective Disorders, 2021, 286, 275-281. | 4.1 | 9 |
| 202 | Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987. | 2.5 | 30 |
| 203 | Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. Neurology, 2021, , 10.1212/WNL.00000000000012145. | 1.1 | 8 |
| 204 | Prediction of future Alzheimer β ™s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042. | 30.7 | 236 |
| 205 | Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2021, 18, 23. | 5.0 | 10 |
| 206 | Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. Journal of Alzheimer's Disease, 2021, 81, 667-677. | 2.6 | 2 |
| 207 | TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640. | 0.8 | 23 |
| 208 | Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. PLoS ONE, 2021, 16, e0248980. | 2.5 | 14 |
| 209 | Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100. | 0.8 | 24 |
| 210 | Common variants in Alzheimer β ™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417. | 12.8 | 140 |
| 211 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496. | 10.2 | 396 |
| 212 | Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214. | 1.9 | 30 |
| 213 | Following spatial A β 2 aggregation dynamics in evolving Alzheimer β ™s disease pathology by imaging stable isotope labeling kinetics. Science Advances, 2021, 7, . | 10.3 | 22 |
| 214 | Clinical Utility of β 2-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 826-833. | 2.1 | 5 |
| 215 | Multi β cohort profiling reveals elevated CSF levels of brain β enriched proteins in Alzheimer β ™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470. | 3.7 | 19 |
| 216 | Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. Aids, 2021, 35, 2129-2136. | 2.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 217 | Spitting image: can saliva biomarkers reflect Alzheimer's disease?. EBioMedicine, 2021, 68, 103437. | 6.1 | 9 |
| 218 | Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601. | 6.0 | 54 |
| 219 | A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400. | 12.8 | 219 |
| 220 | Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136. | 3.3 | 33 |
| 221 | Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160. | 3.1 | 6 |
| 222 | <scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp>. Movement Disorders, 2021, 36, 2595-2604. | 3.9 | 15 |
| 223 | Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257. | 3.9 | 8 |
| 224 | Cognitively unimpaired individuals with a low burden of $A\beta$ pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134. | 6.2 | 8 |
| 225 | Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. Neurological Research, 2021, 43, 1013-1022. | 1.3 | 0 |
| 226 | Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. Journal of Clinical Neuroscience, 2021, 89, 113-121. | 1.5 | 5 |
| 227 | Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma τ biomarkers. EMBO Molecular Medicine, 2021, 13, e14398. | 6.9 | 58 |
| 228 | Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. Menopause, 2021, 28, 1099-1107. | 2.0 | 6 |
| 229 | Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930. | 4.1 | 34 |
| 230 | Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, . | 1.1 | 50 |
| 231 | Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. Journal of Allergy and Clinical Immunology, 2021, 148, 96-98. | 2.9 | 47 |
| 232 | Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304. | 12.8 | 33 |
| 233 | Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516. | 7.6 | 198 |
| 234 | Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research and Therapy, 2021, 23, 189. | 3.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589. | 10.1 | 144 |
| 236 | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. <i>Clinical Neurophysiology</i> , 2021, 132, 1733-1740. | 1.5 | 94 |
| 237 | Amyloid- β^2 positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31. | 3.1 | 13 |
| 238 | CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36. | 3.5 | 9 |
| 239 | Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021, 70, 103512. | 6.1 | 106 |
| 240 | Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599. | 30.7 | 235 |
| 241 | Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 355-366. | 2.6 | 1 |
| 242 | Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937. | 9.0 | 32 |
| 243 | Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135. | 6.2 | 30 |
| 244 | Phenotyping Alzheimer's disease with blood tests. <i>Science</i> , 2021, 373, 626-628. | 12.6 | 21 |
| 245 | Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. <i>Scientific Reports</i> , 2021, 11, 16950. | 3.3 | 5 |
| 246 | Blood Biomarkers for Alzheimer's Disease in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3639. | 2.4 | 17 |
| 247 | The Amyloid- β^2 Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503. | 7.9 | 478 |
| 248 | Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. <i>Intensive Care Medicine</i> , 2021, 47, 984-994. | 8.2 | 50 |
| 249 | Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. <i>Clinical Chemistry</i> , 2021, 67, 1361-1372. | 3.2 | 21 |
| 250 | Head-to-Head Comparison of 8 Plasma Amyloid- β^2 42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1375. | 9.0 | 195 |
| 251 | Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 60, e13-e17. | 2.3 | 0 |
| 252 | The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 161. | 6.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108. | 9.0 | 114 |
| 254 | Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial—The OmegAD Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1291-1301. | 2.6 | 10 |
| 255 | Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial. <i>Critical Care</i> , 2021, 25, 350. | 5.8 | 17 |
| 256 | Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128. | 2.6 | 3 |
| 257 | Amyloid pathology and synaptic loss in pathological aging. <i>Journal of Neurochemistry</i> , 2021, 159, 258-272. | 3.9 | 6 |
| 258 | A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021, 53, 1276-1282. | 21.4 | 430 |
| 259 | Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752. | 10.2 | 220 |
| 260 | Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. <i>Journal of Neurochemistry</i> , 2021, 159, 618-628. | 3.9 | 26 |
| 261 | Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021, 39, 101070. | 7.1 | 21 |
| 262 | Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 151. | 6.2 | 9 |
| 263 | Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241. | 1.9 | 51 |
| 264 | Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. <i>Journal of Affective Disorders</i> , 2021, 293, 429-434. | 4.1 | 5 |
| 265 | A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3. | 3.1 | 5 |
| 266 | Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2021, 116, 103670. | 2.2 | 17 |
| 267 | Association of plasma A β 240/A β 242 ratio and brain A β 2 accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69. | 3.1 | 5 |
| 268 | Brain injury markers in new-onset seizures in adults: A pilot study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 92, 62-67. | 2.0 | 11 |
| 269 | Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864. | 10.0 | 40 |
| 270 | Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients—A PET/MR study. <i>NeuroImage: Clinical</i> , 2021, 30, 102665. | 2.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156. | 0.8 | 174 |
| 272 | Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE ϵ 4 negatives. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12142. | 2.4 | 25 |
| 273 | Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 27. | 4.8 | 207 |
| 274 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021, 73, e3019-e3026. | 5.8 | 131 |
| 275 | Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcb099. | 3.3 | 43 |
| 276 | Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021, 17, 1365-1382. | 0.8 | 43 |
| 277 | OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449. | 7.6 | 54 |
| 278 | The global Alzheimer's Association round robin study on plasma amyloid β 2 methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242. | 2.4 | 17 |
| 279 | Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. <i>Cardiology and Cardiovascular Medicine</i> , 2021, 05, 551-565. | 0.2 | 8 |
| 280 | Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169. | 6.2 | 35 |
| 281 | Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. <i>JAMA Neurology</i> , 2021, 78, 1525. | 9.0 | 19 |
| 282 | Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021, 11, 20375. | 3.3 | 9 |
| 283 | Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021, 18, 573-584. | 1.4 | 3 |
| 284 | Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. <i>Journal of Psychiatric Research</i> , 2021, 144, 255-261. | 3.1 | 3 |
| 285 | Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 175. | 5.2 | 49 |
| 286 | P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098. | 6.9 | 30 |
| 287 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471. | 9.0 | 204 |
| 288 | Evidence of Neuroinflammation and Blood-Brain Barrier Disruption in Women with Preeclampsia and Eclampsia. <i>Cells</i> , 2021, 10, 3045. | 4.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021, 4, 1265. | 4.4 | 4 |
| 290 | Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610. | 3.2 | 7 |
| 291 | Prodromal frontotemporal dementia: clinical features and predictors of progression. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 188. | 6.2 | 8 |
| 292 | Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. <i>Scientific Reports</i> , 2021, 11, 22128. | 3.3 | 31 |
| 293 | Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12241. | 2.4 | 3 |
| 294 | The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans. <i>Frontiers in Physiology</i> , 2021, 12, 769948. | 2.8 | 15 |
| 295 | Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 777475. | 3.4 | 4 |
| 296 | Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 6 |
| 297 | Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198. | 6.2 | 87 |
| 298 | Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 299 | Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 2 |
| 300 | Associations between obstructive sleep apnea, Alzheimer's disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 301 | Establishment of updated biomarker cutoff values for the second-generation Elecsys β -amyloid(1-42), pTau and tTau CSF immunoassays. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 302 | Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 303 | CSF metabolites associated with CSF NeuroToolKit biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 304 | Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 305 | Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloid-positive individuals with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 306 | CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 308 | Brain structural alterations in cognitively unimpaired individuals with discordant amyloid β PET and CSF A β 42 status: Findings using machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 309 | Plasma glial fibrillary acidic protein is an early and specific marker of amyloid β pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 310 | Stress and Alzheimer's disease: Linking salivary cortisol to biomarkers of neurodegeneration and cognitive decline in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 311 | Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 312 | Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 2 |
| 313 | CSF amyloid β , tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middle-aged and older adult APOE ϵ 4 homozygotes, heterozygotes, and non-carriers from the Arizona APOE Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 314 | Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 315 | Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 316 | CSF biomarkers and blood pressure trajectories in normotensive individuals and subjects with controlled and uncontrolled hypertension. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 317 | A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 318 | Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 2 |
| 319 | Microstructural alterations in medial temporal and frontal white matter tracts are associated with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 320 | Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A β pathology and preclinical application. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 321 | Synergistic effects of CSF A β 42 and p-Tau on functional resting-state connectivity in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 322 | Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 2 |
| 323 | Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 324 | Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Associations between plasma p-tau17, in vivo brain pathology and cognition in individuals with autosomal-dominant Alzheimer's disease: Findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 326 | Amyloid aggregation in temporal regions is associated with longitudinal memory decline in cognitively unimpaired <i>ApoE</i> ϵ 4 carriers. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 327 | Plasma p-tau181 and p-tau231 offer complementary information to identify Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 328 | Associations between mean apparent propagator MRI and cerebrospinal fluid markers of AD pathology, neurodegeneration, and glial activation, in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 329 | Apolipoprotein ϵ 4 genotype modifies the association between blood-brain barrier permeability and both grey and white matter integrity in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 330 | Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching β -amyloid biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 331 | Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 332 | Inflammatory biomarkers are associated with cerebral large artery thickening and dilatation in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 333 | Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 334 | Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 1 |
| 335 | Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, e049531. | 0.8 | 0 |
| 336 | Amyloid status is associated with deficits in connected speech language. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 337 | Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 338 | Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle-aged adults with and without evidence of β -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 339 | Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |
| 340 | Plasma pTau isoform assessment across disease stages. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 3 |
| 341 | Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 3 |
| 342 | CSF sTREM2 predicts markers of blood brain barrier integrity and amyloid beta metabolism independent of <i>APOE</i> ϵ 4 status. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 344 | Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 345 | Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year-olds. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 346 | Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 347 | Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 348 | A novel antibody-free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 1 |
| 349 | CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 4 |
| 350 | Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 2 |
| 351 | Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 352 | Diet and APOE as moderators of the relationship between trimethylamine N-oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827. | 0.8 | 2 |
| 353 | Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF p-tau/Ab42 ratio in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 354 | Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: Results of the SABBA-CBSC working group. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 355 | Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 356 | Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030. | 0.8 | 0 |
| 357 | A role for inflammaging in β -synuclein-associated breakdown of local sleep in the elderly.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054208. | 0.8 | 0 |
| 358 | Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011. | 0.8 | 0 |
| 359 | Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451. | 0.8 | 0 |
| 360 | CSF A β 242 and A β 240 and their relation to brain soluble and insoluble A β 2 in the 5xFAD mouse model of Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055684. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | The impact of social networks and $\text{APOE}\epsilon 4$ on dementia among older adults: tests of possible interactions. <i>Aging and Mental Health</i> , 2020, 24, 395-404. | 2.8 | 12 |
| 362 | Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , 2020, 25, 2919-2931. | 7.9 | 99 |
| 363 | Acute symptomatic seizures and epilepsy after mechanical thrombectomy. <i>Epilepsy and Behavior</i> , 2020, 104, 106520. | 1.7 | 25 |
| 364 | Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818. | 1.3 | 50 |
| 365 | Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. <i>Neurobiology of Aging</i> , 2020, 86, 54-63. | 3.1 | 136 |
| 366 | Dementia and CSF biomarkers for Alzheimer's disease predict mortality after acute hip fracture. <i>Acta Anaesthesiologica Scandinavica</i> , 2020, 64, 93-103. | 1.6 | 19 |
| 367 | Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 933-938. | 3.2 | 4 |
| 368 | Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020, 16, 262-272. | 0.8 | 47 |
| 369 | Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020, 134, 104645. | 4.4 | 16 |
| 370 | Chemical imaging of evolving amyloid plaque pathology and associated $\text{A}\beta^2$ peptide aggregation in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 152, 602-616. | 3.9 | 15 |
| 371 | Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <i>BMC Neurology</i> , 2020, 20, 10. | 1.8 | 50 |
| 372 | Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study. <i>Annals of Neurology</i> , 2020, 87, 370-382. | 5.3 | 34 |
| 373 | Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8. | 6.2 | 12 |
| 374 | Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 405-414. | 2.1 | 8 |
| 375 | Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. <i>Neurology</i> , 2020, 94, e1181-e1189. | 1.1 | 59 |
| 376 | Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90. | 3.1 | 4 |
| 377 | Glycan biomarkers for Alzheimer disease correlate with $\text{T}\tau$ and $\text{P}\tau$ in cerebrospinal fluid in subjective cognitive impairment. <i>FEBS Journal</i> , 2020, 287, 3221-3234. | 4.7 | 36 |
| 378 | Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 3. | 6.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41. | 1.1 | 20 |
| 380 | Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020, 143, 650-660. | 7.6 | 68 |
| 381 | An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39. | 4.2 | 67 |
| 382 | Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. <i>Clinica Chimica Acta</i> , 2020, 502, 199-200. | 1.1 | 0 |
| 383 | Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. <i>Movement Disorders</i> , 2020, 35, 513-518. | 3.9 | 22 |
| 384 | Postoperative delirium is associated with increased plasma neurofilament light. <i>Brain</i> , 2020, 143, 47-54. | 7.6 | 107 |
| 385 | CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. <i>Cerebral Cortex</i> , 2020, 30, 2295-2306. | 2.9 | 15 |
| 386 | The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 911-919. | 3.2 | 12 |
| 387 | Quality of life of ice hockey players after retirement due to concussions. <i>Concussion</i> , 2020, 5, CNC78. | 1.0 | 5 |
| 388 | Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. <i>Frontiers in Neurology</i> , 2020, 11, 1054. | 2.4 | 45 |
| 389 | Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6864. | 4.1 | 8 |
| 390 | Biomarkers of neuronal damage in saturation diving—a controlled observational study. <i>European Journal of Applied Physiology</i> , 2020, 120, 2773-2784. | 2.5 | 3 |
| 391 | Î2-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130. | 6.2 | 16 |
| 392 | Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1429-1442. | 2.8 | 4 |
| 393 | Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. <i>Clinical Microbiology and Infection</i> , 2020, 27, 1131-1136. | 6.0 | 15 |
| 394 | Association of plasma YKL-40 with brain amyloid-Î2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32. | 3.1 | 18 |
| 395 | Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. <i>Brain Communications</i> , 2020, 2, fcaa099. | 3.3 | 9 |
| 396 | CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88. | 6.2 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | NfL as a biomarker for neurodegeneration and survival in Parkinson disease. <i>Neurology</i> , 2020, 95, e827-e838. | 1.1 | 73 |
| 398 | Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804. | 7.6 | 60 |
| 399 | Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153. | 6.2 | 9 |
| 400 | Admission Levels of Interleukin 10 and Amyloid β 1-40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 549527. | 2.4 | 8 |
| 401 | Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403. | 4.8 | 42 |
| 402 | Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147. | 6.2 | 23 |
| 403 | Fluid Biomarkers for Chronic Traumatic Encephalopathy. <i>Seminars in Neurology</i> , 2020, 40, 411-419. | 1.4 | 14 |
| 404 | Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772. | 7.4 | 640 |
| 405 | Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278. | 7.7 | 209 |
| 406 | Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 143-153. | 3.1 | 34 |
| 407 | Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. <i>Brain Injury</i> , 2020, 34, 1237-1244. | 1.2 | 2 |
| 408 | Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1661-1673. | 3.7 | 27 |
| 409 | NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102463. | 2.0 | 20 |
| 410 | Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. <i>Scientific Reports</i> , 2020, 10, 18075. | 3.3 | 19 |
| 411 | Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , 2020, 10, 555-565. | 1.7 | 18 |
| 412 | Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. <i>In Vivo</i> , 2020, 34, 2577-2586. | 1.3 | 17 |
| 413 | Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 183-190. | 2.6 | 1 |
| 414 | Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 185-194. | 2.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Neurofilament light chain in the vitreous humor of the eye. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 111. | 6.2 | 13 |
| 416 | Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141. | 2.6 | 55 |
| 417 | First amyloid β 1 α 42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503. | 0.8 | 42 |
| 418 | Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368. | 2.6 | 7 |
| 419 | Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3117-3129. | 3.5 | 6 |
| 420 | Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020, 15, 117727192095031. | 2.5 | 74 |
| 421 | Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus. <i>Journal of NeuroVirology</i> , 2020, 26, 719-726. | 2.1 | 14 |
| 422 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , 2020, 15, e0233820. | 2.5 | 8 |
| 423 | Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289. | 8.4 | 39 |
| 424 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in $A\beta$ pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921. | 6.9 | 202 |
| 425 | Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168. | 6.2 | 7 |
| 426 | Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954. | 0.8 | 1 |
| 427 | CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037097. | 0.8 | 0 |
| 428 | Plasma β tau immunoassays, methodological aspects and clinical performance. <i>Alzheimer's and Dementia</i> , 2020, 16, e037515. | 0.8 | 1 |
| 429 | Phospho β tau217 and phospho β tau181 in plasma and CSF as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037520. | 0.8 | 2 |
| 430 | Plasma phospho β tau181 in over 400 cognitively healthy 69 \pm to 71 \pm year olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. <i>Alzheimer's and Dementia</i> , 2020, 16, e037848. | 0.8 | 0 |
| 431 | Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020, 16, e037912. | 0.8 | 0 |
| 432 | Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. <i>Alzheimer's and Dementia</i> , 2020, 16, e038588. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Protective genetic variants in the MS4A gene cluster modulate microglial activity. Alzheimer's and Dementia, 2020, 16, e039431. | 0.8 | 1 |
| 434 | Reduction of neurogranin immunostaining in the hippocampus of postmortem brain of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040707. | 0.8 | 0 |
| 435 | AD biomarker stability for stored CSF based on immunoassay results. Alzheimer's and Dementia, 2020, 16, e040747. | 0.8 | 0 |
| 436 | Associations of dietary patterns and CSF biomarkers for Alzheimer's disease in a population-based sample of 70-year-olds. Alzheimer's and Dementia, 2020, 16, e040800. | 0.8 | 0 |
| 437 | CSF 7-ketocholesterol is related to β -amyloid and white matter microstructure in healthy adults. Alzheimer's and Dementia, 2020, 16, e041015. | 0.8 | 0 |
| 438 | Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041053. | 0.8 | 0 |
| 439 | An ultrasensitive immunoassay for detection of p-tau181 in blood. Alzheimer's and Dementia, 2020, 16, e041238. | 0.8 | 1 |
| 440 | Association of plasma YKL40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753. | 0.8 | 0 |
| 441 | Characterization of monomeric and soluble aggregated β 2 in Down's syndrome and Alzheimer's disease brains. Alzheimer's and Dementia, 2020, 16, e042479. | 0.8 | 0 |
| 442 | Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530. | 0.8 | 0 |
| 443 | A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e042578. | 0.8 | 0 |
| 444 | Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e042955. | 0.8 | 0 |
| 445 | Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer's disease from healthy controls. Alzheimer's and Dementia, 2020, 16, e043467. | 0.8 | 1 |
| 446 | The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043979. | 0.8 | 0 |
| 447 | CSF NFL levels and neuroimaging-derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimer's pathologic framework. Alzheimer's and Dementia, 2020, 16, e043987. | 0.8 | 2 |
| 448 | Elevated levels of synaptic protein GAP43 associate with brain tauopathy, atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044098. | 0.8 | 2 |
| 449 | Amyloid β 2, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044444. | 0.8 | 0 |
| 450 | Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Cerebrospinal fluid levels of SNAP-25 and SYT1 in Alzheimer's and Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e044515. | 0.8 | 3 |
| 452 | Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720. | 0.8 | 0 |
| 453 | The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722. | 0.8 | 0 |
| 454 | Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044733. | 0.8 | 0 |
| 455 | Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. Alzheimer's and Dementia, 2020, 16, e044780. | 0.8 | 0 |
| 456 | Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e044802. | 0.8 | 3 |
| 457 | Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808. | 0.8 | 0 |
| 458 | APOE ϵ 4 shapes temporoparietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092. | 0.8 | 0 |
| 459 | Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. Alzheimer's and Dementia, 2020, 16, e045137. | 0.8 | 0 |
| 460 | Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171. | 0.8 | 0 |
| 461 | Incidence of subjective cognitive decline is associated with amyloid β pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293. | 0.8 | 0 |
| 462 | CSF phosphorylated tau β 217 is increased in Alzheimer's and Creutzfeldt-Jakob diseases and correlates with amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045296. | 0.8 | 4 |
| 463 | Amyloid β -positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715. | 0.8 | 0 |
| 464 | Impact of APOE ϵ 4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e045828. | 0.8 | 1 |
| 465 | DNA methylation differences associated with peripheral biomarkers in the EMIF β AD cohort. Alzheimer's and Dementia, 2020, 16, e045853. | 0.8 | 0 |
| 466 | Levels of amyloid β 2 in cerebrospinal fluid predicts cognition five years later: A population-based study of 70-year-olds. Alzheimer's and Dementia, 2020, 16, e045969. | 0.8 | 0 |
| 467 | Multimodal genome-wide meta-analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009. | 0.8 | 0 |
| 468 | Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 469 | Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimer's disease-related neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e046095. | 0.8 | 0 |
| 470 | Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102. | 0.8 | 0 |
| 471 | Microglial activation indexed by [11 C]PBR28 is associated with synaptic depletion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046191. | 0.8 | 0 |
| 472 | Hypertension accentuates reductions in CSF A β 42 in elderly depressives. <i>Alzheimer's and Dementia</i> , 2020, 16, e046299. | 0.8 | 0 |
| 473 | Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046355. | 0.8 | 0 |
| 474 | SNAP25 reflects amyloid- and tau-related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic dysfunction in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e046358. | 0.8 | 3 |
| 475 | Exploring genetic contributors to neuroprotection from AD pathologies: A genome-wide association study. <i>Alzheimer's and Dementia</i> , 2020, 16, e046417. | 0.8 | 0 |
| 476 | Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e046463. | 0.8 | 0 |
| 477 | Plasma-based biomarkers for A β 2 and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046490. | 0.8 | 0 |
| 478 | Blood-brain barrier permeability measured by 7 β -hydroxy-3 α -cholestenic acid in CSF associates with Alzheimer's pathology biomarkers in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046582. | 0.8 | 0 |
| 479 | Insulin resistance is related to cognitive decline but not biomarkers of Alzheimer's pathology in adults without dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e047022. | 0.8 | 0 |
| 480 | Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/A β 42 status in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e047156. | 0.8 | 0 |
| 481 | CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020, 16, e047247. | 0.8 | 1 |
| 482 | Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine-use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020, 16, e047394. | 0.8 | 0 |
| 483 | Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. <i>Alzheimer's and Dementia</i> , 2020, 16, e047517. | 0.8 | 0 |
| 484 | Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539. | 0.8 | 2 |
| 485 | Alzheimer's pathologic change indexed by CSF B α -amyloid42 associates with longitudinal alterations in myelin content. <i>Alzheimer's and Dementia</i> , 2020, 16, e047629. | 0.8 | 0 |
| 486 | Ultra-performance liquid chromatography-tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. <i>Alzheimer's and Dementia</i> , 2020, 16, e040373. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 487 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020, 11, 6252. | 12.8 | 36 |
| 488 | Steroidâ€Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020, 88, 423-427. | 5.3 | 230 |
| 489 | Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 161-168. | 2.1 | 2 |
| 490 | Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1143-1156. | 2.6 | 7 |
| 491 | Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 937-947. | 2.6 | 13 |
| 492 | Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 883-895. | 0.8 | 10 |
| 493 | Losing the identity of a hockey player: the long-term effects of concussions. <i>Concussion</i> , 2020, 5, CNC74. | 1.0 | 4 |
| 494 | A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 60-70. | 3.1 | 35 |
| 495 | Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 513-521. | 10.2 | 97 |
| 496 | APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65. | 6.2 | 28 |
| 497 | Human plasma biomarker responses to inhalational general anaesthesia without surgery. <i>British Journal of Anaesthesia</i> , 2020, 125, 282-290. | 3.4 | 27 |
| 498 | Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>. <i>Alzheimer's and Dementia</i> , 2020, 16, 1358-1371. | 0.8 | 120 |
| 499 | Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 941-953. | 2.6 | 9 |
| 500 | Blood Biomarkers: Democratizing Alzheimer's Diagnostics. <i>Neuron</i> , 2020, 106, 881-883. | 8.1 | 38 |
| 501 | Admission Levels of Total Tau and Î²-Amyloid Isoforms Î²40 and Î²42 in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 325. | 2.4 | 11 |
| 502 | Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 139. | 3.4 | 4 |
| 503 | Dextran- Versus Crystalloid-Based Prime in Cardiac Surgery: A Prospective Randomized Pilot Study. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1541-1547. | 1.3 | 12 |
| 504 | Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020, 95, e1754-e1759. | 1.1 | 304 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 505 | Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid- β 42 and White Matter Microstructure in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 643-656. | 2.6 | 8 |
| 506 | A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458. | 1.7 | 15 |
| 507 | Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2020, 11, 376. | 2.4 | 20 |
| 508 | Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. <i>BMC Medicine</i> , 2020, 18, 140. | 5.5 | 34 |
| 509 | The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. <i>Frontiers in Neurology</i> , 2020, 11, 149. | 2.4 | 14 |
| 510 | Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism – A pilot study. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 19, 100218. | 1.4 | 4 |
| 511 | APOE- ϵ 4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120. | 2.9 | 7 |
| 512 | The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21. | 6.2 | 183 |
| 513 | Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. <i>Cerebral Cortex</i> , 2020, 30, 2144-2156. | 2.9 | 13 |
| 514 | Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 965-974. | 2.6 | 14 |
| 515 | Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961. | 1.1 | 50 |
| 516 | CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. <i>IBRO Reports</i> , 2020, 8, 136-142. | 0.3 | 5 |
| 517 | Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967. | 1.9 | 93 |
| 518 | Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- β Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301. | 2.6 | 3 |
| 519 | CXCL13 in patients with facial palsy caused by varicella zoster virus and <i>Borrelia burgdorferi</i> : a comparative study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115095. | 1.8 | 2 |
| 520 | Neurofilament light as a biomarker in traumatic brain injury. <i>Neurology</i> , 2020, 95, e610-e622. | 1.1 | 127 |
| 521 | Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. <i>Neurology</i> , 2020, 95, e623-e636. | 1.1 | 136 |
| 522 | Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386. | 30.7 | 643 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 523 | Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397. | 30.7 | 471 |
| 524 | Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNI/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020, 66, 587-597. | 3.2 | 15 |
| 525 | Accelerated neuronal and synaptic maturation by BrainPhys medium increases A β secretion and alters A β peptide ratios from iPSC-derived cortical neurons. <i>Scientific Reports</i> , 2020, 10, 601. | 3.3 | 26 |
| 526 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20. | 6.2 | 32 |
| 527 | Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 19. | 6.2 | 29 |
| 528 | Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020, 41, 2004-2013. | 3.6 | 22 |
| 529 | Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1363-1372. | 2.6 | 18 |
| 530 | Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. <i>Archives of Toxicology</i> , 2020, 94, 2517-2522. | 4.2 | 43 |
| 531 | Neurofilament light in former athletes: a potential biomarker of neurodegeneration and progression. <i>European Journal of Neurology</i> , 2020, 27, 1170-1177. | 3.3 | 12 |
| 532 | A β deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387. | 10.3 | 202 |
| 533 | An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284. | 10.1 | 121 |
| 534 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433. | 10.2 | 668 |
| 535 | Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2020, 93, 1-15. | 3.1 | 11 |
| 536 | Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1211-1220. | 2.6 | 22 |
| 537 | Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. <i>Frontiers in Neurology</i> , 2020, 11, 586610. | 2.4 | 4 |
| 538 | Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423. | | 1 |
| 539 | Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12099. | 2.4 | 16 |
| 540 | Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12137. | 2.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 541 | Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls. <i>Translational Psychiatry</i> , 2020, 10, 58. | 4.8 | 8 |
| 542 | Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020, 11, 619. | 12.8 | 67 |
| 543 | Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. <i>Scientific Reports</i> , 2020, 10, 22400. | 3.3 | 6 |
| 544 | Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792. | 7.6 | 89 |
| 545 | Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 617-625. | 2.1 | 19 |
| 546 | Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020, 95, e3026-e3035. | 1.1 | 31 |
| 547 | Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. <i>PLoS ONE</i> , 2020, 15, e0236384. | 2.5 | 23 |
| 548 | Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043169. | 0.8 | 1 |
| 549 | Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043060. | 0.8 | 0 |
| 550 | White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA study). <i>Alzheimer's and Dementia</i> , 2020, 16, e043027. | 0.8 | 0 |
| 551 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 552 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 553 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 554 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 555 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 556 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 557 | Title is missing!. , 2020, 17, e1003289. | | 0 |
| 558 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 559 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820. | | 0 |
| 560 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820. | | 0 |
| 561 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820. | | 0 |
| 562 | Title is missing!. , 2020, 15, e0236384. | | 0 |
| 563 | Title is missing!. , 2020, 15, e0236384. | | 0 |
| 564 | Title is missing!. , 2020, 15, e0236384. | | 0 |
| 565 | Title is missing!. , 2020, 15, e0236384. | | 0 |
| 566 | Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. Journal of Neurochemistry, 2019, 151, 488-506. | 3.9 | 34 |
| 567 | Antibodyâ€‘based methods for the measurement of Î±â€‘synuclein concentration in human cerebrospinal fluid â€‘ method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138. | 3.9 | 44 |
| 568 | Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. Neuropsychobiology, 2019, 77, 13-22. | 1.9 | 20 |
| 569 | Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion, 2019, 46, 228-235. | 3.4 | 10 |
| 570 | The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, . | 12.4 | 170 |
| 571 | Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232. | 2.0 | 20 |
| 572 | Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. Journal of Neurology, 2019, 266, 2796-2806. | 3.6 | 49 |
| 573 | Plasma neurofilament light chain concentration is increased in anorexia nervosa. Translational Psychiatry, 2019, 9, 180. | 4.8 | 26 |
| 574 | Ultrasensitive Detection of Plasma Amyloid-Î² as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 71, 775-783. | 2.6 | 38 |
| 575 | Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimerâ€™s disease. Clinical Mass Spectrometry, 2019, 14, 74-82. | 1.9 | 9 |
| 576 | Plasma tau complements CSF tau and Pâ€‘tau in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 483-492. | 2.4 | 86 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 577 | Characterization of Cerebrospinal Fluid BACE1 Species. <i>Molecular Neurobiology</i> , 2019, 56, 8603-8616. | 4.0 | 4 |
| 578 | Sex differences in the genetic predictors of Alzheimer's pathology. <i>Brain</i> , 2019, 142, 2581-2589. | 7.6 | 65 |
| 579 | Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 120. | 5.2 | 64 |
| 580 | Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease. <i>Brain Research</i> , 2019, 1720, 146305. | 2.2 | 34 |
| 581 | Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. <i>NeuroImage: Clinical</i> , 2019, 23, 101895. | 2.7 | 28 |
| 582 | Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1556-1564. | 2.3 | 32 |
| 583 | Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 2278-2288. | 2.8 | 11 |
| 584 | Plasma neurofilament light chain and amyloid- β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186. | 7.2 | 41 |
| 585 | Autocatalytic amplification of Alzheimer-associated A β 42 peptide aggregation in human cerebrospinal fluid. <i>Communications Biology</i> , 2019, 2, 365. | 4.4 | 46 |
| 586 | Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 525-535. | 2.6 | 16 |
| 587 | Comparison of variables associated with cerebrospinal fluid neurofilament, total τ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447. | 0.8 | 38 |
| 588 | Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170. | 6.9 | 228 |
| 589 | Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. <i>PLoS ONE</i> , 2019, 14, e0225178. | 2.5 | 12 |
| 590 | Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 700-709. | 2.4 | 35 |
| 591 | "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157. | 0.8 | 23 |
| 592 | Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5. | 5.2 | 125 |
| 593 | Was it worth it? Older adults' experiences of participating in a population-based cohort study "a focus group study. <i>BMC Geriatrics</i> , 2019, 19, 224. | 2.7 | 13 |
| 594 | Growth factors and neurotrophins in patients with stress-related exhaustion disorder. <i>Psychoneuroendocrinology</i> , 2019, 109, 104415. | 2.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 595 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488. | 0.8 | 46 |
| 596 | Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53. | 3.1 | 48 |
| 597 | Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82. | 6.2 | 51 |
| 598 | CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 81. | 6.2 | 72 |
| 599 | Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 281-290. | 2.6 | 7 |
| 600 | Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689. | 2.4 | 48 |
| 601 | Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. <i>Infectious Diseases</i> , 2019, 51, 838-846. | 2.8 | 7 |
| 602 | Age-Dependent Relationship Between Plasma A β 40 and A β 42 and Total Tau Levels in Cognitively Normal Subjects. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 222. | 3.4 | 29 |
| 603 | NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. <i>Brain Injury</i> , 2019, 33, 456-462. | 1.2 | 50 |
| 604 | Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. <i>Journal of Neuroinflammation</i> , 2019, 16, 16. | 7.2 | 22 |
| 605 | Head trauma in sports and risk for dementia. <i>Journal of Internal Medicine</i> , 2019, 285, 591-593. | 6.0 | 3 |
| 606 | A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250. | 7.7 | 87 |
| 607 | Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019, 72, 30-38. | 1.9 | 60 |
| 608 | Method comparison study of the Elecsys® β -Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019, 72, 7-14. | 1.9 | 30 |
| 609 | Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035. | 9.0 | 455 |
| 610 | Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060. | 9.0 | 282 |
| 611 | CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1117-1123. | 1.9 | 61 |
| 612 | NFL is a marker of treatment response in children with SMA treated with nusinersen. <i>Journal of Neurology</i> , 2019, 266, 2129-2136. | 3.6 | 104 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 613 | Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163. | 3.6 | 41 |
| 614 | Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. <i>Neurobiology of Aging</i> , 2019, 80, 111-115. | 3.1 | 6 |
| 615 | Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2242-2249. | 1.6 | 40 |
| 616 | Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898. | 0.8 | 290 |
| 617 | Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260. | 1.1 | 160 |
| 618 | Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1213-1220. | 2.6 | 12 |
| 619 | Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2019, 76, 969. | 9.0 | 65 |
| 620 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827. | 0.8 | 62 |
| 621 | Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 147-156. | 2.1 | 15 |
| 622 | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775. | 0.8 | 122 |
| 623 | Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 551-559. | 2.6 | 6 |
| 624 | Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy—A pilot study. <i>Journal of Affective Disorders</i> , 2019, 253, 449-453. | 4.1 | 17 |
| 625 | Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 177-183. | 2.1 | 3 |
| 626 | A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 2850-2862. | 3.4 | 129 |
| 627 | CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 846-853. | 1.9 | 46 |
| 628 | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 129-138. | 3.7 | 22 |
| 629 | Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 791. | 9.0 | 436 |
| 630 | Identification of neurotoxic cross-linked amyloid- β dimers in the Alzheimer's brain. <i>Brain</i> , 2019, 142, 1441-1457. | 7.6 | 74 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 631 | Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. <i>Journal of Internal Medicine</i> , 2019, 286, 101-110. | 6.0 | 23 |
| 632 | Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27. | 6.2 | 82 |
| 633 | Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019, 494, 79-93. | 1.1 | 30 |
| 634 | Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. <i>Journal of Neurotrauma</i> , 2019, 36, 2400-2406. | 3.4 | 27 |
| 635 | Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. <i>PLoS ONE</i> , 2019, 14, e0212815. | 2.5 | 12 |
| 636 | Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654. | 0.8 | 90 |
| 637 | Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753. | 0.8 | 82 |
| 638 | Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- β and tau. <i>Neurobiology of Aging</i> , 2019, 80, 11-20. | 3.1 | 80 |
| 639 | Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 870-881. | 1.9 | 623 |
| 640 | Amyloid β 242 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 114-124. | 1.5 | 3 |
| 641 | Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1565-1573. | 2.3 | 11 |
| 642 | Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 740-746. | 1.9 | 23 |
| 643 | Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 111-121. | 2.6 | 8 |
| 644 | CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586. | 10.2 | 393 |
| 645 | APOE ϵ 4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. <i>Ageing and Society</i> , 2019, 39, 1951-1975. | 1.7 | 6 |
| 646 | Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141. | 3.1 | 23 |
| 647 | Mass Spectrometric Analysis of Lewy Body-Enriched α -Synuclein in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2019, 18, 2109-2120. | 3.7 | 49 |
| 648 | Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019, 9, 5522. | 3.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 649 | Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460. | 3.3 | 7 |
| 650 | Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated A β 42 Species A β 5 α 42. ACS Chemical Neuroscience, 2019, 10, 2374-2384. | 3.5 | 16 |
| 651 | Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 19. | 6.2 | 65 |
| 652 | Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neurosciences, 2019, 97, 34-42. | 2.2 | 55 |
| 653 | Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10. | 10.8 | 61 |
| 654 | A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances, 2019, 5, eaau7220. | 10.3 | 59 |
| 655 | Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. Schizophrenia Research, 2019, 208, 490-492. | 2.0 | 5 |
| 656 | Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863. | 5.4 | 75 |
| 657 | Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84. | 2.4 | 69 |
| 658 | Sleep deprivation and plasma biomarkers for Alzheimer's disease. Sleep Medicine, 2019, 57, 92-93. | 1.6 | 8 |
| 659 | Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica, 2019, 139, 462-468. | 2.1 | 21 |
| 660 | Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2019, 49, e13082. | 3.4 | 6 |
| 661 | A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. Neuroscience Letters, 2019, 701, 125-131. | 2.1 | 43 |
| 662 | Pyroglutamation of amyloid- β 42 (A β 42) followed by A β 1 α 40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732. | 3.4 | 49 |
| 663 | Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2178-2189. | 3.4 | 56 |
| 664 | FTS3 α 1 α 01: UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY IN RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS. Alzheimer's and Dementia, 2019, 15, P872. | 0.8 | 1 |
| 665 | P4 α 531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO β -AMYLOID POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517. | 0.8 | 0 |
| 666 | P4 α 546: THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1526. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 667 | P4â€579: LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER'S DISEASE PATHOLOGIC FRAMEWORK. Alzheimer's and Dementia, 2019, 15, P1542. | 0.8 | 0 |
| 668 | Altered CSF levels of monoamines in hereditary spastic paraparesis 10. Neurology: Genetics, 2019, 5, e344. | 1.9 | 2 |
| 669 | CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105. | 6.2 | 31 |
| 670 | P4â€573: PROXIMITY TO PARENTAL ONSET AND APOE ϵ 4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLE-AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1539. | 0.8 | 0 |
| 671 | P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515. | 0.8 | 0 |
| 672 | CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. Neurology: Neuroimmunology and Neuroinflammation, 2019, 6, . | 6.0 | 7 |
| 673 | O3â€02â€01: APOE ϵ 4 ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETA-AMYLOID AND GRAY MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P877. | 0.8 | 0 |
| 674 | F4â€05â€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1224. | 0.8 | 0 |
| 675 | P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX A β 2 PEPTIDES IN HUMAN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1492. | 0.8 | 0 |
| 676 | P4â€535: PRESENTATION OF A ROUTINE-USE PREANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS. Alzheimer's and Dementia, 2019, 15, P1520. | 0.8 | 0 |
| 677 | P4â€589: COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRI-BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2019, 15, P1547. | 0.8 | 0 |
| 678 | O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545. | 0.8 | 2 |
| 679 | ICâ€Pâ€093: PLASMA AMYLOID β AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD. Alzheimer's and Dementia, 2019, 15, P82. | 0.8 | 0 |
| 680 | Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry, 2019, 1, 100007. | 1.0 | 10 |
| 681 | P4â€519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1513. | 0.8 | 0 |
| 682 | ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P64. | 0.8 | 1 |
| 683 | ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P65. | 0.8 | 0 |
| 684 | ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND Voxel-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P66. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 685 | A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Big Data Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938. | 3.7 | 70 |
| 686 | ICP-MS: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2019, 15, P24. | 0.8 | 0 |
| 687 | Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94. | 6.2 | 20 |
| 688 | Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23. | 1.7 | 28 |
| 689 | Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports, 2019, 9, 17309. | 3.3 | 5 |
| 690 | Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683. | 30.7 | 328 |
| 691 | Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697. | 2.5 | 17 |
| 692 | Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A β 2(1-42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024. | 3.3 | 123 |
| 693 | Repeated lumbar punctures within 3 days may affect CSF biomarker levels. Fluids and Barriers of the CNS, 2019, 16, 37. | 5.0 | 8 |
| 694 | Salivary Biomarkers for Alzheimer's Disease and Related Disorders. Neurology and Therapy, 2019, 8, 83-94. | 3.2 | 54 |
| 695 | Peripheral Biomarkers for Alzheimer's Disease: Update and Progress. Neurology and Therapy, 2019, 8, 33-36. | 3.2 | 7 |
| 696 | Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17. | 2.2 | 82 |
| 697 | Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438. | 4.4 | 11 |
| 698 | Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neuroscience Letters, 2019, 698, 58-63. | 2.1 | 57 |
| 699 | The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. European Journal of Epidemiology, 2019, 34, 191-209. | 5.7 | 89 |
| 700 | Head trauma in sports - clinical characteristics, epidemiology and biomarkers. Journal of Internal Medicine, 2019, 285, 624-634. | 6.0 | 39 |
| 701 | Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187. | 9.0 | 66 |
| 702 | The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. International Journal of Geriatric Psychiatry, 2019, 34, 415-419. | 2.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 703 | Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019, 16, 76-81. | 3.1 | 9 |
| 704 | Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163. | 6.4 | 30 |
| 705 | Association of PTHrP levels in CSF with Alzheimer's disease biomarkers. <i>Clinical Mass Spectrometry</i> , 2019, 14, 124-129. | 1.9 | 5 |
| 706 | Accurate risk estimation of β -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204. | 0.8 | 49 |
| 707 | Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , 2019, 76, 64. | 9.0 | 158 |
| 708 | Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64. | 0.8 | 97 |
| 709 | Vitamin D supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 172-176. | 2.1 | 18 |
| 710 | Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33. | 2.2 | 163 |
| 711 | Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. <i>NeuroImage: Clinical</i> , 2019, 21, 101586. | 2.7 | 24 |
| 712 | Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296. | 7.7 | 128 |
| 713 | The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 8, 476-491. | 1.3 | 7 |
| 714 | Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 1551-1560. | 3.4 | 56 |
| 715 | Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318. | 9.0 | 161 |
| 716 | A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144. | 2.3 | 25 |
| 717 | Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 417-434. | 3.9 | 15 |
| 718 | The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 89-102. | 7.7 | 64 |
| 719 | GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 458-467. | 2.3 | 30 |
| 720 | Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. <i>Brain Imaging and Behavior</i> , 2019, 13, 41-52. | 2.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 721 | Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. <i>World Journal of Oncology</i> , 2019, 10, 169-175. | 1.5 | 28 |
| 722 | Title is missing!. , 2019, 14, e0226276. | | 0 |
| 723 | Title is missing!. , 2019, 14, e0226276. | | 0 |
| 724 | Title is missing!. , 2019, 14, e0226276. | | 0 |
| 725 | Title is missing!. , 2019, 14, e0226276. | | 0 |
| 726 | Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 188-195. | 2.4 | 51 |
| 727 | Induction of Amyloid- β 242 Production by Fipronil and Other Pyrazole Insecticides. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1663-1681. | 2.6 | 23 |
| 728 | Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937. | 3.2 | 37 |
| 729 | CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481. | 0.8 | 468 |
| 730 | Low Cerebrospinal Fluid A β 242 and A β 240 are Related to White Matter Lesions in Cognitively Normal Elderly. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1877-1886. | 2.6 | 13 |
| 731 | Neurofilament light and tau as blood biomarkers for sports-related concussion. <i>Neurology</i> , 2018, 90, e1780-e1788. | 1.1 | 147 |
| 732 | Cerebrospinal fluid markers of extracellular matrix remodelling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy. <i>Journal of Internal Medicine</i> , 2018, 284, 211-225. | 6.0 | 12 |
| 733 | Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. <i>Journal of Neurotrauma</i> , 2018, 35, 2351-2356. | 3.4 | 43 |
| 734 | Plasma Amyloid- β 2 (A β 242) Correlates with Cerebrospinal Fluid A β 242 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1857-1863. | 2.6 | 100 |
| 735 | NIA- β AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562. | 0.8 | 5,861 |
| 736 | Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- β Load and Cognitive Performance in Cognitively Normal Elderly Participants. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 479-487. | 2.6 | 50 |
| 737 | Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1802-1817. | 3.5 | 60 |
| 738 | Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 143-150. | 2.1 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 739 | The Past and the Future of Alzheimer's Disease Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1125-1140. | 2.6 | 106 |
| 740 | Prevalence of preclinical Alzheimer disease. <i>Neurology</i> , 2018, 90, e1682-e1691. | 1.1 | 82 |
| 741 | Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery. <i>JAMA Neurology</i> , 2018, 75, 542. | 9.0 | 96 |
| 742 | Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763. | 0.8 | 61 |
| 743 | Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. <i>EBioMedicine</i> , 2018, 28, 21-30. | 6.1 | 250 |
| 744 | Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 385-397. | 2.6 | 81 |
| 745 | Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886. | 1.1 | 28 |
| 746 | Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 417-427. | 2.6 | 5 |
| 747 | Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018, 90, e717-e723. | 1.1 | 65 |
| 748 | Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1453-1458. | 3.6 | 10 |
| 749 | Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Sleep</i> , 2018, 41, . | 1.1 | 73 |
| 750 | Evolution of cerebrospinal fluid total α -synuclein in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 4-8. | 2.2 | 31 |
| 751 | Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 374-385. | 1.3 | 31 |
| 752 | Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395. | 1.1 | 83 |
| 753 | Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. <i>Neurology</i> , 2018, 90, e518-e524. | 1.1 | 176 |
| 754 | CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 162-171. | 3.7 | 30 |
| 755 | Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: $A\beta_{42}$, total τ , phosphorylated τ , NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501. | 0.8 | 91 |
| 756 | Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. <i>Brain</i> , 2018, 141, 459-471. | 7.6 | 143 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 757 | A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8. | 6.2 | 111 |
| 758 | White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30. | 6.2 | 40 |
| 759 | Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376. | 7.7 | 114 |
| 760 | Cerebrospinal fluid β -amyloid ₄₂ and neurofilament light relate to white matter hyperintensities. <i>Neurobiology of Aging</i> , 2018, 68, 18-25. | 3.1 | 39 |
| 761 | Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924. | 0.8 | 58 |
| 762 | Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901. | 0.8 | 8 |
| 763 | Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 4260. | 3.3 | 25 |
| 764 | Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018, 83, 447-455. | 1.3 | 83 |
| 765 | Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1046-1054. | 3.0 | 149 |
| 766 | Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. <i>Cerebral Cortex</i> , 2018, 28, 2775-2785. | 2.9 | 40 |
| 767 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328. | 2.6 | 215 |
| 768 | A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700131. | 1.6 | 87 |
| 769 | Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 91-98. | 2.1 | 20 |
| 770 | Inhibition of β -Secretase Leads to an Increase in Presenilin-1. <i>Molecular Neurobiology</i> , 2018, 55, 5047-5058. | 4.0 | 19 |
| 771 | Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84. | 11.0 | 133 |
| 772 | CSF neurofilament light concentration is increased in presymptomatic <i>CHMP2B</i> mutation carriers. <i>Neurology</i> , 2018, 90, e157-e163. | 1.1 | 11 |
| 773 | Increased midlife triglycerides predict brain β -amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018, 90, e73-e81. | 1.1 | 76 |
| 774 | Central and peripheral leptin and agouti-related protein during and after pregnancy in relation to weight change. <i>Clinical Endocrinology</i> , 2018, 88, 263-271. | 2.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 775 | Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 933-943. | 5.6 | 174 |
| 776 | O2â€03â€05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLEâ€AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P617. | 0.8 | 0 |
| 777 | P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: AÎ²_{1â€42}, TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154. | 0.8 | 1 |
| 778 | P3â€161: ALTERATIONS IN ALZHEIMERâ€ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELLâ€DERIVED CORTICAL NEURONS. Alzheimer's and Dementia, 2018, 14, P1129. | 0.8 | 0 |
| 779 | P3â€267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P1178. | 0.8 | 1 |
| 780 | P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350. | 0.8 | 0 |
| 781 | P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782. | 0.8 | 0 |
| 782 | O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623. | 0.8 | 0 |
| 783 | P1â€007: POOR SLEEP IS ASSOCIATED WITH CSFâ€MARKERS OF ALZHEIMER'S DISEASE IN 70â€YEARâ€OLDS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P265. | 0.8 | 0 |
| 784 | F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603. | 0.8 | 0 |
| 785 | ICâ€Pâ€018: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED LATE MIDDLEâ€AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P23. | 0.8 | 2 |
| 786 | P1â€217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE. Alzheimer's and Dementia, 2018, 14, P361. | 0.8 | 0 |
| 787 | P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327. | 0.8 | 0 |
| 788 | P1â€279: BIMODAL DISTRIBUTION OF THE CSF AÎ² ⁴² /AÎ² ⁴⁰ RATIO IN CLINICAL LABORATORY PRACTICE. Alzheimer's and Dementia, 2018, 14, P389. | 0.8 | 0 |
| 789 | P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. Alzheimer's and Dementia, 2018, 14, P275. | 0.8 | 0 |
| 790 | Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology, 2018, 18, 202. | 1.8 | 21 |
| 791 | D10â€...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€TM's disease. , 2018, , . | | 0 |
| 792 | P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 793 | O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036. | 0.8 | 0 |
| 794 | P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510. | 0.8 | 0 |
| 795 | P1â€262: NEUROFILAMENT LIGHT PROTEIN IS ASSOCIATED WITH COGNITIVE DECLINE WITHIN THE ATN MODEL. Alzheimer's and Dementia, 2018, 14, P381. | 0.8 | 0 |
| 796 | P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174. | 0.8 | 0 |
| 797 | Chronic traumatic encephalopathy: fluid biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 158, 323-333. | 1.8 | 14 |
| 798 | CSF sTREM2 in deliriumâ€relation to Alzheimerâ€™s disease CSF biomarkers AÎ²42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304. | 7.2 | 36 |
| 799 | P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767. | 0.8 | 0 |
| 800 | DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670. | 0.8 | 1 |
| 801 | P1â€001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI. Alzheimer's and Dementia, 2018, 14, P261. | 0.8 | 0 |
| 802 | The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 124. | 6.2 | 273 |
| 803 | Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders, 2018, 46, 346-357. | 1.5 | 41 |
| 804 | Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853. | 7.7 | 370 |
| 805 | Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652. | 10.1 | 434 |
| 806 | Interlaboratory validation of cerebrospinal fluid Î±â€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470. | 2.4 | 7 |
| 807 | Abnormal CSF amyloid-Î²42 and tau levels in hip fracture patients without dementia. PLoS ONE, 2018, 13, e0204695. | 2.5 | 19 |
| 808 | Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. BMJ Open Sport and Exercise Medicine, 2018, 4, e000433. | 2.9 | 58 |
| 809 | Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgeryâ€a randomized trial. Journal of Neuroinflammation, 2018, 15, 283. | 7.2 | 38 |
| 810 | Cerebrospinal fluid protein markers in PD patients after DBS-STN surgeryâ€A retrospective analysis of patients that underwent surgery between 1993 and 2001. Clinical Neurology and Neurosurgery, 2018, 174, 174-179. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 811 | Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1505-1521. | 0.8 | 163 |
| 812 | Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. <i>Nutrition Research</i> , 2018, 60, 13-25. | 2.9 | 12 |
| 813 | Early predictors of mortality in parkinsonism and Parkinson disease. <i>Neurology</i> , 2018, 91, e2045-e2056. | 1.1 | 111 |
| 814 | No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. <i>PLoS ONE</i> , 2018, 13, e0206466. | 2.5 | 31 |
| 815 | DTâ€02â€01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1668. | 0.8 | 0 |
| 816 | Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. <i>Neurochemistry International</i> , 2018, 121, 38-49. | 3.8 | 20 |
| 817 | Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 87. | 6.2 | 13 |
| 818 | Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610. | 2.7 | 11 |
| 819 | Therapeutic potential for peripheral clearance of misfolded brain proteins. <i>Nature Reviews Neurology</i> , 2018, 14, 637-638. | 10.1 | 8 |
| 820 | Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. <i>Molecular Neurodegeneration</i> , 2018, 13, 47. | 10.8 | 21 |
| 821 | Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589. | 10.1 | 1,177 |
| 822 | From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S271-S279. | 2.6 | 66 |
| 823 | Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals AÎ² Aggregation Dependent Anionic Lipid Accumulations and Metabolism. <i>Analytical Chemistry</i> , 2018, 90, 8130-8138. | 6.5 | 39 |
| 824 | Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. <i>European Neuropsychopharmacology</i> , 2018, 28, 783-794. | 0.7 | 18 |
| 825 | A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1325-1335. | 2.6 | 6 |
| 826 | Neurofilament relates to white matter microstructure in older adults. <i>Neurobiology of Aging</i> , 2018, 70, 233-241. | 3.1 | 48 |
| 827 | Trisomy of human chromosome 21 enhances amyloid-Î² deposition independently of an extra copy of APP. <i>Brain</i> , 2018, 141, 2457-2474. | 7.6 | 96 |
| 828 | Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE Î´4. <i>SSM - Population Health</i> , 2018, 5, 171-179. | 2.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 829 | Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872. | 7.7 | 87 |
| 830 | Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2058-2066. | 2.3 | 27 |
| 831 | Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , 2018, 307, 129-132. | 4.1 | 51 |
| 832 | The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333. | 0.8 | 87 |
| 833 | No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127. | 3.1 | 51 |
| 834 | CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877. | 1.1 | 207 |
| 835 | Biomarkers for Alzheimer's disease: current status and prospects for the future. <i>Journal of Internal Medicine</i> , 2018, 284, 643-663. | 6.0 | 550 |
| 836 | Levels of ADAM10 are reduced in Alzheimer's disease CSF. <i>Journal of Neuroinflammation</i> , 2018, 15, 213. | 7.2 | 39 |
| 837 | Association of cerebrospinal fluid α -synuclein with total and phospho τ ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631. | 0.8 | 45 |
| 838 | Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5151-5154. | 3.6 | 55 |
| 839 | Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 71. | 6.2 | 216 |
| 840 | Cerebrospinal fluid tau, β , and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1159-1170. | 0.8 | 96 |
| 841 | Commentary: Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Frontiers in Neurology</i> , 2018, 9, 201. | 2.4 | 31 |
| 842 | The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. <i>Cell Death and Disease</i> , 2018, 9, 775. | 6.3 | 10 |
| 843 | Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90. | 3.1 | 15 |
| 844 | Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. <i>PLoS ONE</i> , 2018, 13, e0196025. | 2.5 | 29 |
| 845 | Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 209. | 7.2 | 94 |
| 846 | The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 62. | 5.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 847 | Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5. | 6.2 | 94 |
| 848 | Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32. | 6.2 | 79 |
| 849 | Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. <i>JAMA Neurology</i> , 2018, 75, 989. | 9.0 | 223 |
| 850 | Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45. | 6.2 | 11 |
| 851 | Cerebrospinal fluid GAP-43 in early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879293. | 1.0 | 8 |
| 852 | Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. <i>Journal of Proteome Research</i> , 2018, 17, 4072-4084. | 3.7 | 5 |
| 853 | Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 90-99. | 1.5 | 9 |
| 854 | Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2018, 24, 695-701. | 2.1 | 35 |
| 855 | Serum neurofilament light chain in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 98-101. | 2.2 | 38 |
| 856 | Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812. | 1.4 | 59 |
| 857 | Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. <i>PLoS ONE</i> , 2018, 13, e0193492. | 2.5 | 21 |
| 858 | The nonlinear relationship between cerebrospinal fluid A β 42 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0191240. | 2.5 | 41 |
| 859 | D08...Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntington's disease: a retrospective cohort analysis. , 2018, , . | | 0 |
| 860 | HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. <i>Molecular Neurobiology</i> , 2017, 54, 188-199. | 4.0 | 13 |
| 861 | CSF A β 42 "an excellent but complicated Alzheimer's biomarker" a route to standardisation. <i>Clinica Chimica Acta</i> , 2017, 467, 27-33. | 1.1 | 104 |
| 862 | Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 62-71. | 3.0 | 81 |
| 863 | Genome-wide association study identifies <i>MAPT</i> locus influencing human plasma tau levels. <i>Neurology</i> , 2017, 88, 669-676. | 1.1 | 33 |
| 864 | Plasma concentrations of free amyloid β 2 cannot predict the development of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 778-782. | 0.8 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 865 | Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury—Reply. <i>JAMA Neurology</i> , 2017, 74, 363. | 9.0 | 4 |
| 866 | Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. <i>Translational Psychiatry</i> , 2017, 7, e995-e995. | 4.8 | 56 |
| 867 | Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555. | 2.6 | 10 |
| 868 | CSF YKL40 and GAP43 are related to suicidal ideation in older women. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 351-357. | 4.5 | 8 |
| 869 | Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71. | 2.2 | 34 |
| 870 | Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912. | 0.8 | 32 |
| 871 | The effects of different familial Alzheimer's disease mutations on APP processing in vivo. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 9. | 6.2 | 32 |
| 872 | Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2017, 24, 703-712. | 3.3 | 97 |
| 873 | Astroglial activation and altered amyloid metabolism in human repetitive concussion. <i>Neurology</i> , 2017, 88, 1400-1407. | 1.1 | 39 |
| 874 | Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , 2017, 133, 839-856. | 7.7 | 199 |
| 875 | Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <i>Journal of Neuroimmunology</i> , 2017, 306, 25-30. | 2.3 | 17 |
| 876 | Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 391-402. | 3.2 | 16 |
| 877 | Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 397-403. | 1.7 | 58 |
| 878 | Accuracy of cerebrospinal fluid A β 1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunoassay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1545-1554. | 2.3 | 14 |
| 879 | Blood-based NfL. <i>Neurology</i> , 2017, 88, 930-937. | 1.1 | 369 |
| 880 | The immune response of the human brain to abdominal surgery. <i>Annals of Neurology</i> , 2017, 81, 572-582. | 5.3 | 87 |
| 881 | Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003. | 0.8 | 39 |
| 882 | Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. <i>Neurology</i> , 2017, 88, 1788-1794. | 1.1 | 280 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 883 | Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 284-290. | 3.7 | 23 |
| 884 | Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 195-201. | 4.1 | 69 |
| 885 | The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 31. | 6.2 | 36 |
| 886 | A Season of American Football Is Not Associated with Changes in Plasma Tau. <i>Journal of Neurotrauma</i> , 2017, 34, 3295-3300. | 3.4 | 14 |
| 887 | Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. <i>Scientific Reports</i> , 2017, 7, 3485. | 3.3 | 18 |
| 888 | Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870. | 5.3 | 768 |
| 889 | Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115. | 0.9 | 14 |
| 890 | Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 829-840. | 2.6 | 31 |
| 891 | Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. <i>Brain Research</i> , 2017, 1668, 12-19. | 2.2 | 53 |
| 892 | Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360. | 3.8 | 46 |
| 893 | Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 821-828. | 2.6 | 12 |
| 894 | C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477. | 3.3 | 28 |
| 895 | Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1245-1254. | 2.6 | 54 |
| 896 | Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 761-770. | 3.1 | 114 |
| 897 | Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , The, 2017, 16, 601-609. | 10.2 | 272 |
| 898 | Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126. | 2.4 | 197 |
| 899 | The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 767-775. | 2.8 | 4 |
| 900 | Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 387-393. | 2.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 901 | The recency ratio is associated with reduced CSF glutamate in late-life depression. <i>Neurobiology of Learning and Memory</i> , 2017, 141, 14-18. | 1.9 | 10 |
| 902 | Alterations in the Balance of Amyloid- β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1281-1291. | 2.6 | 4 |
| 903 | Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 557. | 9.0 | 664 |
| 904 | Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 8, 870-882. | 4.8 | 53 |
| 905 | Clinical validity of cerebrospinal fluid A β 42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 196-213. | 3.1 | 100 |
| 906 | Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. <i>Analytical Chemistry</i> , 2017, 89, 4685-4694. | 6.5 | 60 |
| 907 | The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 327-334. | 2.6 | 8 |
| 908 | Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284. | 0.8 | 113 |
| 909 | Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295. | 0.8 | 108 |
| 910 | Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017, 51, 104-112. | 3.1 | 154 |
| 911 | Expanding the cerebrospinal fluid endopeptidome. <i>Proteomics</i> , 2017, 17, 1600384. | 2.2 | 28 |
| 912 | Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. <i>ACS Chemical Neuroscience</i> , 2017, 8, 347-355. | 3.5 | 66 |
| 913 | Serum neurofilament light in familial Alzheimer disease. <i>Neurology</i> , 2017, 89, 2167-2175. | 1.1 | 204 |
| 914 | Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237. | 1.1 | 307 |
| 915 | 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975. | 10.2 | 175 |
| 916 | Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700100. | 1.6 | 28 |
| 917 | Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214. | 12.8 | 596 |
| 918 | Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. <i>Scientific Reports</i> , 2017, 7, 14114. | 3.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 919 | Serum tau and neurological outcome in cardiac arrest. <i>Annals of Neurology</i> , 2017, 82, 665-675. | 5.3 | 86 |
| 920 | Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. <i>Expert Review of Proteomics</i> , 2017, 14, 1007-1020. | 3.0 | 21 |
| 921 | Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334. | 2.6 | 35 |
| 922 | A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333. | 3.3 | 45 |
| 923 | Gut microbiome alterations in Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13537. | 3.3 | 1,256 |
| 924 | Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. <i>Journal of Neuroimmunology</i> , 2017, 312, 15-18. | 2.3 | 46 |
| 925 | A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <i>Neurology and Therapy</i> , 2017, 6, 15-24. | 3.2 | 211 |
| 926 | Alzheimer's disease markers in the aged sheep (<i>Ovis aries</i>). <i>Neurobiology of Aging</i> , 2017, 58, 112-119. | 3.1 | 30 |
| 927 | CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9. | 3.1 | 84 |
| 928 | CSF Aβ42 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223. | 6.9 | 156 |
| 929 | Absolute Quantification of Aβ ₁₋₄₂ in CSF Using a Mass Spectrometric Reference Measurement Procedure. <i>Journal of Visualized Experiments</i> , 2017, , . | 0.3 | 3 |
| 930 | Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <i>European Journal of Neurology</i> , 2017, 24, 1326. | 3.3 | 71 |
| 931 | [P3-273]: EFFECTS OF RISPERIDONE AND GALANTAMINE TREATMENT ON ALZHEIMER BIOMARKER LEVELS IN CEREBROSPINAL FLUID. <i>Alzheimer's and Dementia</i> , 2017, 13, P1047. | 0.8 | 0 |
| 932 | Low-dose β-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 211-219. | 2.2 | 6 |
| 933 | [P2-141]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP. <i>Alzheimer's and Dementia</i> , 2017, 13, P661. | 0.8 | 0 |
| 934 | Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017, 7, e018177. | 1.9 | 4 |
| 935 | [P2-367]: CROSS-SECTIONAL CORRELATION BETWEEN GTP1-TAU-PET AND CSF TAU AS MEASURES OF TAU BURDEN IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P766. | 0.8 | 0 |
| 936 | Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1017-1026. | 2.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 937 | Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023. | 7.1 | 170 |
| 938 | Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. Journal of Neural Transmission, 2017, 124, 1641-1645. | 2.8 | 3 |
| 939 | [P4â€“182]: A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATEâ€“LIFE MAJOR DEPRESSIVE DISORDER. Alzheimer's and Dementia, 2017, 13, P1332. | 0.8 | 1 |
| 940 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676. | 10.2 | 464 |
| 941 | Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology, 2017, 89, 445-453. | 1.1 | 166 |
| 942 | Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid Î² clearance pathway. Molecular Neurodegeneration, 2017, 12, 18. | 10.8 | 17 |
| 943 | Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. Journal of Neural Transmission, 2017, 124, 1135-1143. | 2.8 | 19 |
| 944 | The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). Virus Research, 2017, 227, 220-230. | 2.2 | 24 |
| 945 | Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurology, 2017, 74, 41. | 9.0 | 147 |
| 946 | Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€“remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304. | 3.9 | 124 |
| 947 | Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. Journal of Neurotrauma, 2017, 34, 1124-1127. | 3.4 | 104 |
| 948 | CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiology of Aging, 2017, 49, 138-144. | 3.1 | 60 |
| 949 | Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumabâ€“treated multiple sclerosis. European Journal of Neurology, 2017, 24, 112-121. | 3.3 | 35 |
| 950 | A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer's and Dementia, 2017, 13, 59-71. | 0.8 | 112 |
| 951 | Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. NeuroMolecular Medicine, 2017, 19, 154-160. | 3.4 | 18 |
| 952 | Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. Journal of NeuroVirology, 2017, 23, 106-112. | 2.1 | 22 |
| 953 | The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. American Journal of Geriatric Psychiatry, 2017, 25, 170-177. | 1.2 | 13 |
| 954 | Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492. | 9.0 | 97 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 955 | Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- β^2 Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891. | 2.6 | 6 |
| 956 | [P1â€“221]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P328. | 0.8 | 0 |
| 957 | [P1â€“028]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€“GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, 0.8 P243. | 0.8 | 0 |
| 958 | [P2â€“536]: THE PREVALENCE OF PRECLINICAL ALZHEIMER'S DISEASE IN A POPULATION STUDY OF 70â€“YEARâ€“OLDS. Alzheimer's and Dementia, 2017, 13, P848. | 0.8 | 2 |
| 959 | [P3â€“084]: Nâ€“TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH INâ€“HOUSE CLEAVAGEâ€“SPECIFIC ANTIBODY. Alzheimer's and Dementia, 2017, 13, P964. | 0.8 | 0 |
| 960 | [P3â€“132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985. | 0.8 | 0 |
| 961 | [P3â€“171]: ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P1000. | 0.8 | 0 |
| 962 | [P3â€“174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1000. | 0.8 | 0 |
| 963 | [P3â€“198]: PREDICTION PERFORMANCE OF ALPHAâ€“SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHTâ€“PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P1011. | 0.8 | 0 |
| 964 | [P3â€“423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€“AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P1128. | 0.8 | 0 |
| 965 | [P3â€“425]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1130. | 0.8 | 0 |
| 966 | [P4â€“152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β^2 â€“AMYLOID (1â€“42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. Alzheimer's and Dementia, 2017, 13, P1316. | 0.8 | 1 |
| 967 | [P4â€“163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. Alzheimer's and Dementia, 2017, 13, P1322. | 0.8 | 0 |
| 968 | [P1â€“150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN <i>IL1RAP</i> AND ALZHEIMER'Sâ€“RELATED CSFâ€“BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300. | 0.8 | 0 |
| 969 | [ICâ€“Pâ€“048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P41. | 0.8 | 0 |
| 970 | [ICâ€“Pâ€“049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€“AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41. | 0.8 | 0 |
| 971 | [P1â€“187]: NOVEL METHOD FOR OLIGOMERIC β^2 DETECTION REVEALS INTRACELLULAR ACCUMULATION OF β^2 UPON LOWâ€“DOSE TREATMENT WITH A GAMMAâ€“SECRETASE INHIBITOR. Alzheimer's and Dementia, 2017, 13, P314. | 0.8 | 0 |
| 972 | [P1â€“268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY. Alzheimer's and Dementia, 2017, 13, P352. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 973 | [P1â€“281]: DIAGNOSTIC PERFORMANCE USING CSF YKLâ€“40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P357. | 0.8 | 0 |
| 974 | [P1â€“282]: DIAGNOSTIC ACCURACY OF CSF AÎ²1â€“42, Pâ€“TAU, Tâ€“TAU, NEUROFILAMENT LIGHT CHAIN, NEUROGRANIN, YKLâ€“40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P358. | 0.8 | 0 |
| 975 | [P1â€“287]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€“GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P361. | 0.8 | 0 |
| 976 | [P1â€“611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE É“4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530. | 0.8 | 0 |
| 977 | [P2â€“158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION. Alzheimer's and Dementia, 2017, 13, P668. | 0.8 | 0 |
| 978 | [P2â€“208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. Alzheimer's and Dementia, 2017, 13, P689. | 0.8 | 1 |
| 979 | [P2â€“211]: AMYLOIDâ€“242 (AÎ²42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOIDâ€“POSITIVE VERSUS AMYLOIDâ€“NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC ATâ€“RISK8 FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690. | | 0 |
| 980 | [P2â€“241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P703. | 0.8 | 0 |
| 981 | [P2â€“246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706. | 0.8 | 0 |
| 982 | [P2â€“260]: TWOâ€“LEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P712. | 0.8 | 0 |
| 983 | [P2â€“262]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHTâ€“READ STUDY. Alzheimer's and Dementia, 2017, 13, P713. | 0.8 | 0 |
| 984 | [F3â€“01â€“03]: THE PATHOGENIC BASIS OF THE ALZHEIMER CSF BIOMARKERS: WHAT DO WE KNOW TODAY?. Alzheimer's and Dementia, 2017, 13, P878. | 0.8 | 0 |
| 985 | [O4â€“02â€“01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON'S AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1228. | 0.8 | 0 |
| 986 | [O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230. | 0.8 | 0 |
| 987 | [P4â€“392]: NOVEL ASSAYS TO MONITOR AÎ² PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTER INHIBITION OF BACE. Alzheimer's and Dementia, 2017, 13, P1478. | 0.8 | 0 |
| 988 | [P4â€“470]: PRESYNAPTIC DEGRADATION IN ALZHEIMER'S DISEASE MEASURED BY NOVEL GAPâ€“43 ELISA IN CSF. Alzheimer's and Dementia, 2017, 13, P1513. | 0.8 | 0 |
| 989 | [ICâ€“Pâ€“171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P128. | 0.8 | 0 |
| 990 | Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , . | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 991 | Factors Influencing Successful Lumbar Puncture in Alzheimer Research. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 287-294. | 1.3 | 18 |
| 992 | Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood. <i>British Journal of Sports Medicine</i> , 2017, 51, A6.3-A7. | 6.7 | 1 |
| 993 | [P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. <i>Alzheimer's and Dementia</i> , 2017, 13, P960. | 0.8 | 0 |
| 994 | Microstructural white matter alterations in preclinical Alzheimerâ€™s disease detected using free water elimination diffusion tensor imaging. <i>PLoS ONE</i> , 2017, 12, e0173982. | 2.5 | 104 |
| 995 | Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 201-210. | 2.6 | 11 |
| 996 | Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017, 17, 170. | 1.8 | 70 |
| 997 | Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimerâ€™s disease, and neuronal injury in humans: a cohort study. <i>Journal of Neuroinflammation</i> , 2017, 14, 193. | 7.2 | 15 |
| 998 | Preclinical effects of APOE Î¼4 on cerebrospinal fluid AÎ²42 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87. | 6.2 | 22 |
| 999 | A phase III randomized trial of gantenerumab in prodromal Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95. | 6.2 | 396 |
| 1000 | Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 243-252. | 2.6 | 15 |
| 1001 | High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. <i>Journal of Lipid Research</i> , 2017, 58, 1482-1489. | 4.2 | 14 |
| 1002 | Tau or neurofilament lightâ€“Which is the more suitable biomarker for Huntingtonâ€™s disease?. <i>PLoS ONE</i> , 2017, 12, e0172762. | 2.5 | 40 |
| 1003 | Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. <i>PLoS ONE</i> , 2017, 12, e0176760. | 2.5 | 18 |
| 1004 | Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1373-1383. | 2.6 | 51 |
| 1005 | A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1353-1363. | 2.6 | 28 |
| 1006 | Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 225. | 3.4 | 18 |
| 1007 | Blood biomarkers indicate mild neuroaxonal injury and increased amyloid production after transient hypoxia during breath-hold diving. <i>Brain Injury</i> , 2016, 30, 1226-1230. | 1.2 | 23 |
| 1008 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547. | 1.1 | 1,216 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1009 | Update on fluid biomarkers for concussion. <i>Concussion</i> , 2016, 1, CNC12. | 1.0 | 11 |
| 1010 | <i>Apolipoprotein E</i> polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 466-474. | 2.1 | 12 |
| 1011 | Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 30. | 6.2 | 110 |
| 1012 | Cerebrospinal fluid levels of insulin, leptin, and agouti-related protein in relation to BMI in pregnant women. <i>Obesity</i> , 2016, 24, 1299-1304. | 3.0 | 10 |
| 1013 | Cerebral white matter lesions – associations with A β isoforms and amyloid PET. <i>Scientific Reports</i> , 2016, 6, 20709. | 3.3 | 52 |
| 1014 | Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 473-484. | 2.6 | 93 |
| 1015 | Associations between Performance on the Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1395-1408. | 2.6 | 40 |
| 1016 | Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 1184-1196. | 6.9 | 219 |
| 1017 | Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170. | 2.6 | 23 |
| 1018 | Cerebrospinal Fluid A β 42/40 Corresponds Better than A β 42 to Amyloid PET in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 813-822. | 2.6 | 191 |
| 1019 | Serum erythropoietin and outcome after ischaemic stroke: a prospective study. <i>BMJ Open</i> , 2016, 6, e009827. | 1.9 | 9 |
| 1020 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 19-35. | 2.6 | 35 |
| 1021 | <i>sTREM-2</i> cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476. | 6.9 | 392 |
| 1022 | Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 303-313. | 2.6 | 44 |
| 1023 | The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41. | 6.2 | 121 |
| 1024 | Specific Triazine Herbicides Induce Amyloid- β 42 Production. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1593-1605. | 2.6 | 14 |
| 1025 | Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496. | 2.6 | 14 |
| 1026 | Preclinical Amyloid- β 2 and Axonal Degeneration Pathology in Delirium. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 371-379. | 2.6 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1027 | D2â€¦Cerebrospinal fluid biomarkers in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A34.2-A34. | 1.9 | 0 |
| 1028 | P3-129: Psychological Stress in Midlife Associated with Higher Levels of CSF T-TAU and AB40 in Late-Life: A 25-YEAR Longitudinal Population Study of Women. , 2016, 12, P869-P869. | | 0 |
| 1029 | O1â€05â€01: Increased Amyloidogenic app Processing in Apoe E4â€Negative Individuals with Cerebral Bâ€Amyloidosis. Alzheimer's and Dementia, 2016, 12, P182. | 0.8 | 0 |
| 1030 | O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe Î•4 Carriers'. , 2016, 12, P375-P376. | | 0 |
| 1031 | P1â€172: Combined Added Value of Cerebrospinal Fluid Neurogranin and Neurofilament Light Chain Protein in the Diagnosis and Classification Of Prodromal and Alzheimerâ€™s Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468. | 0.8 | 0 |
| 1032 | ICâ€Pâ€050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P41. | 0.8 | 0 |
| 1033 | P1â€322: Fourâ€Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. Alzheimer's and Dementia, 2016, 12, P548. | 0.8 | 0 |
| 1034 | P1â€344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P561. | 0.8 | 0 |
| 1035 | P1â€410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. Alzheimer's and Dementia, 2016, 12, P591. | 0.8 | 0 |
| 1036 | P2â€151: Cerebrospinal Fluid Biomarker Profile of Amyloid, TAU, Synaptic, Microglial, and Lysosomal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloidâ€Pet Status. Alzheimer's and Dementia, 2016, 12, P672. | 0.8 | 0 |
| 1037 | P2â€152: Characterization of the Postsynaptic Protein Neurogranin in Different Brain Regions in Patients with Familial Alzheimer's Disease, Alzheimer's Disease, Pathological Aging And Healthy Controls. Alzheimer's and Dementia, 2016, 12, P672. | 0.8 | 0 |
| 1038 | P2â€142: Comparison of Tâ€Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P667. | 0.8 | 0 |
| 1039 | ICâ€Pâ€123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. Alzheimer's and Dementia, 2016, 12, P91. | 0.8 | 0 |
| 1040 | P2â€430: The Prevalence of Pathological CSF Abetaâ€42 and ITS Relation to Education in a Population Sample of Older People from Sweden. Alzheimer's and Dementia, 2016, 12, P810. | 0.8 | 0 |
| 1041 | P3-162: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Chain Protein in the Classification of Prodromal and Alzheimerâ€™s Disease Dementia. , 2016, 12, P881-P881. | | 1 |
| 1042 | P3-165: Plasma Biomarker Profile of Amyloid, TAU, and Neuronal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status. , 2016, 12, P882-P883. | | 0 |
| 1043 | P3-193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury. , 2016, 12, P896-P897. | | 0 |
| 1044 | P4-114: Cerebrospinal Fluid Biomarkers of Neuronal Injury in Chronic Traumatic Brain Injury. , 2016, 12, P1056-P1056. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1045 | FTS3-01-03: Biomarkers for Vascular Contributions to Dementia. Alzheimer's and Dementia, 2016, 12, P276. | 0.8 | 0 |
| 1046 | 01-05-06: Stability of Amyloid- β (1-42) in Fresh Versus Frozen Human Cerebrospinal Fluid Samples as Measured with the Elecsys [®] β -Amyloid(1-42) Immunoassay. Alzheimer's and Dementia, 2016, 12, P185. | 0.8 | 0 |
| 1047 | 01-10-01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P198. | 0.8 | 3 |
| 1048 | 01-11-05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic. Alzheimer's and Dementia, 2016, 12, P203. | 0.8 | 1 |
| 1049 | 03-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. , 2016, 12, P285-P286. | | 0 |
| 1050 | 03-09-01: Distinct Cognitive Trajectories in Late Middle-Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306. | 0.8 | 0 |
| 1051 | 04-10-01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2016, 12, P357. | 0.8 | 0 |
| 1052 | P1-012: A Population-Based Study on the Relation Between Sleep Disturbance and Beta-Amyloid 42 in Cerebrospinal Fluid in 70-Year-Olds. , 2016, 12, P404-P404. | | 0 |
| 1053 | P1-028: Does Calcium Supplementation Increase the Risk of Dementia in Women With Cerebrovascular Disease? A Five Year Follow-Up of Older Swedish Women. , 2016, 12, P412-P412. | | 0 |
| 1054 | P1-171: Added Diagnostic Value of Cerebrospinal Fluid Neurogranin in the Classification of Prodromal and Alzheimer's Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468. | 0.8 | 0 |
| 1055 | P1-177: How Accurate are Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease? A Systematic Review. , 2016, 12, P471-P472. | | 0 |
| 1056 | P1-181: State-Dependent Alterations in CSF A β 42 Levels in Cognitively-Intact Elderly With Late Life Major Depression. Alzheimer's and Dementia, 2016, 12, P473. | 0.8 | 0 |
| 1057 | P1-197: Evaluation TM , A Novel Multiplex Technology for Simultaneous Quantification of Inflammation Markers, β -Amyloid and TAU Proteins. Alzheimer's and Dementia, 2016, 12, P479. | 0.8 | 0 |
| 1058 | P1-204: Neurogranin: a Specific Synaptic Biomarker for Amnesic Alzheimer's Disease?. Alzheimer's and Dementia, 2016, 12, P483. | 0.8 | 0 |
| 1059 | P4-312: Progress on the Development of Certified Reference Materials for AB1-42. Alzheimer's and Dementia, 2016, 12, P1153. | 0.8 | 0 |
| 1060 | P4-313: Commutability of the Candidate Certified Reference Materials for the Standardization of A β 1-42 Measurements in Human Cerebrospinal Fluid. Alzheimer's and Dementia, 2016, 12, P1153. | 0.8 | 0 |
| 1061 | P4-324: Plasma Neurofilament Light Concentration Predicts Long-Term Outcome an Acute Stroke. Alzheimer's and Dementia, 2016, 12, P1158. | 0.8 | 0 |
| 1062 | Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 873-886. | 2.6 | 101 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1063 | Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737. | 3.3 | 81 |
| 1064 | Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Translational Psychiatry, 2016, 6, e744-e744. | 4.8 | 69 |
| 1065 | Serum Neurofilament Light in American Football Athletes over the Course of a Season. Journal of Neurotrauma, 2016, 33, 1784-1789. | 3.4 | 110 |
| 1066 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761. | 1.1 | 66 |
| 1067 | CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology, The, 2016, 15, 673-684. | 10.2 | 1,413 |
| 1068 | Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1655-1661. | 2.3 | 517 |
| 1069 | Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 112-117. | 2.3 | 43 |
| 1070 | CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253. | 1.6 | 64 |
| 1071 | Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553. | 7.6 | 107 |
| 1072 | Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurology, 2016, 73, 1308. | 9.0 | 96 |
| 1073 | Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835. | 1.1 | 371 |
| 1074 | Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ϵ 4 allele. Brain Research, 2016, 1651, 11-16. | 2.2 | 25 |
| 1075 | Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20. | 3.7 | 137 |
| 1076 | Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225. | 3.7 | 163 |
| 1077 | Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease. Movement Disorders, 2016, 31, 898-905. | 3.9 | 136 |
| 1078 | Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2016, 13, 13. | 5.0 | 38 |
| 1079 | Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522. | 4.7 | 15 |
| 1080 | Reference measurement procedure for CSF amyloid beta ($A\beta_{42}$) and the $A\beta_{42}/A\beta_{40}$ ratio: a cross-validation study against amyloid PET. Journal of Neurochemistry, 2016, 139, 651-658. | | 78 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1081 | Calcium supplementation and risk of dementia in women with cerebrovascular disease. <i>Neurology</i> , 2016, 87, 1674-1680. | 1.1 | 35 |
| 1082 | Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. <i>Journal of Neural Transmission</i> , 2016, 123, 1443-1447. | 2.8 | 39 |
| 1083 | Plasma β -amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801. | 3.3 | 442 |
| 1084 | Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e271. | 6.0 | 118 |
| 1085 | Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64. | 2.6 | 18 |
| 1086 | Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 98-102. | 2.4 | 62 |
| 1087 | Fluid biomarkers for mild traumatic brain injury and related conditions. <i>Nature Reviews Neurology</i> , 2016, 12, 563-574. | 10.1 | 215 |
| 1088 | Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. <i>Neurology</i> , 2016, 87, 1329-1336. | 1.1 | 354 |
| 1089 | The clinical value of fluid biomarkers for dementia diagnosis – Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 1204-1205. | 10.2 | 7 |
| 1090 | O2A€10A€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P252. | 0.8 | 0 |
| 1091 | Traumatic brain injuries. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16084. | 30.5 | 380 |
| 1092 | Increased amyloidogenic APP processing in APOE ϵ 4-negative individuals with cerebral β -amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918. | 12.8 | 48 |
| 1093 | Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. <i>Scientific Reports</i> , 2016, 6, 29200. | 3.3 | 65 |
| 1094 | Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. <i>Scientific Reports</i> , 2016, 6, 36791. | 3.3 | 281 |
| 1095 | Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. <i>Sleep</i> , 2016, 39, 1253-1260. | 1.1 | 44 |
| 1096 | Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 283-294. | 1.3 | 33 |
| 1097 | High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 22. | 6.2 | 39 |
| 1098 | Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid $A\beta$ 42 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016, 39, 2041-2048. | 1.1 | 140 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1099 | No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016, 11, 65. | 10.8 | 16 |
| 1100 | Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice. <i>Movement Disorders</i> , 2016, 31, 836-847. | 3.9 | 54 |
| 1101 | Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016, 23, 796-806. | 3.3 | 46 |
| 1102 | APOE ϵ 4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1159-1166. | 0.8 | 29 |
| 1103 | Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. <i>Brain</i> , 2016, 139, 2261-2274. | 7.6 | 41 |
| 1104 | Cerebrospinal fluid ratios with A β ₄₂ predict preclinical brain β -amyloid accumulation. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 27-38. | 2.4 | 44 |
| 1105 | Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016, 13, 4. | 2.1 | 22 |
| 1106 | Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1943-1945. | 2.0 | 98 |
| 1107 | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3. | 10.8 | 236 |
| 1108 | Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. <i>Journal of Neurotrauma</i> , 2016, 33, 1995-1999. | 3.4 | 71 |
| 1109 | Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835. | 1.1 | 170 |
| 1110 | Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595. | 3.0 | 73 |
| 1111 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323. | 0.8 | 1,318 |
| 1112 | CSF A β ₄₂ /A β ₄₀ and A β ₄₂ /A β ₃₈ ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165. | 3.7 | 329 |
| 1113 | CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016, 208, 195-196. | 2.8 | 19 |
| 1114 | Alzheimer's disease. <i>Lancet</i> , 2016, 388, 505-517. | 13.7 | 2,430 |
| 1115 | Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1826-34. | 7.1 | 492 |
| 1116 | A single dose of the β -secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 11. | 6.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1117 | YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 52-57. | 2.3 | 64 |
| 1118 | Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <i>Neurochemistry International</i> , 2016, 93, 1-5. | 3.8 | 17 |
| 1119 | Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016, 3, 135-140. | 6.1 | 360 |
| 1120 | Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A β 1-42 in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, 517-526. | 0.8 | 254 |
| 1121 | Round robin test on quantification of amyloid A β 1-42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59. | 0.8 | 46 |
| 1122 | Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , 2016, 73, 60. | 9.0 | 354 |
| 1123 | Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191. | 2.3 | 49 |
| 1124 | Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163. | 0.8 | 179 |
| 1125 | C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. <i>Oncotarget</i> , 2016, 7, 19382-19394. | 1.8 | 21 |
| 1126 | Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 841-850. | 1.8 | 49 |
| 1127 | P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease. , 2015, 11, P766-P766. | | 1 |
| 1128 | P2-063: A β 240 and A β 242 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology. , 2015, 11, P507-P507. | | 0 |
| 1129 | Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 420-428. | 2.4 | 28 |
| 1130 | P1-316: The role of lysozyme in Alzheimer's disease. , 2015, 11, P477-P478. | | 6 |
| 1131 | P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort. , 2015, 11, P659-P660. | | 0 |
| 1132 | P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid- β 1-42 levels in patients with Alzheimer's disease. , 2015, 11, P364-P365. | | 0 |
| 1133 | P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE ϵ 4 carriers. , 2015, 11, P427-P428. | | 0 |
| 1134 | Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056. | 30.5 | 1,210 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1135 | Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function. Journal of Alzheimer's Disease, 2015, 44, 1313-1322. | 2.6 | 26 |
| 1136 | Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 93-100. | 2.6 | 35 |
| 1137 | Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741. | 2.6 | 18 |
| 1138 | Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191. | 2.6 | 34 |
| 1139 | Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid- β Levels in Patients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078. | 2.6 | 28 |
| 1140 | Biomarkers in Sporadic and Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317. | 2.6 | 75 |
| 1141 | 37 Years of Body Mass Index and Dementia: Effect Modification by the APOE Genotype: Observations from the Prospective Population Study of Women in Gothenburg, Sweden. Journal of Alzheimer's Disease, 2015, 48, 1119-1127. | 2.6 | 27 |
| 1142 | Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 637-646. | 2.6 | 40 |
| 1143 | Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411. | 2.4 | 26 |
| 1144 | P4-038: Factors influencing lumbar puncture participation in Alzheimer's research. , 2015, 11, P780-P780. | | 3 |
| 1145 | P1-099: White matter lesions but not lacunes are associated with the CSF levels of $A\beta_{38}$ and $A\beta_{40}$, and to a lesser degree with CSF $A\beta_{42}$. , 2015, 11, P376-P377. | | 0 |
| 1146 | P2-062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease?. , 2015, 11, P506-P507. | | 0 |
| 1147 | APLP1 as a cerebrospinal fluid biomarker for β -secretase modulator treatment. Alzheimer's Research and Therapy, 2015, 7, 77. | 6.2 | 9 |
| 1148 | Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with $A\beta_{42}$ and influence of disease on the total $A\beta_{42}/A\beta_{40}$ ratio. Journal of Neurochemistry, 2015, 135, 1049-1058. | 3.9 | 18 |
| 1149 | Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 74. | 6.2 | 109 |
| 1150 | Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE ϵ 4 Carriers. Journal of Alzheimer's Disease, 2015, 46, 525-533. | 2.6 | 65 |
| 1151 | Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667. | 2.6 | 14 |
| 1152 | A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179. | 2.4 | 348 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1153 | The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216. | 2.4 | 36 |
| 1154 | The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events. <i>Frontiers in Neuroscience</i> , 2015, 9, 345. | 2.8 | 66 |
| 1155 | Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls. <i>PLoS ONE</i> , 2015, 10, e0127100. | 2.5 | 38 |
| 1156 | Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 250-258. | 2.4 | 75 |
| 1157 | First effects of rising amyloid- β^2 in transgenic mouse brain: synaptic transmission and gene expression. <i>Brain</i> , 2015, 138, 1992-2004. | 7.6 | 67 |
| 1158 | Rarity of the Alzheimer Disease—Protective <i>APP</i> A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209. | 9.0 | 41 |
| 1159 | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560. | 0.8 | 205 |
| 1160 | CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. <i>European Neuropsychopharmacology</i> , 2015, 25, 1091-1098. | 0.7 | 47 |
| 1161 | P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794. | | 0 |
| 1162 | P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?. , 2015, 11, P340-P340. | | 0 |
| 1163 | P1-110: Predictors of cognitive decline in elderly depressives. , 2015, 11, P381-P382. | | 0 |
| 1164 | P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384. | | 1 |
| 1165 | P1-116: Correlation of the modified innotest β^2 -amyloid 1-42 with a lc-ms/ms candidate reference method. , 2015, 11, P385-P385. | | 1 |
| 1166 | P2-074: Differences in the TREM2 levels in the CSF of Alzheimer's disease cases and controls. , 2015, 11, P511-P511. | | 0 |
| 1167 | P4-036: CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease. , 2015, 11, P779-P779. | | 0 |
| 1168 | P1-033: A candidate reference method for analysis of amyloid beta 1-42 (β^2 1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer. , 2015, 11, P349-P349. | | 0 |
| 1169 | Independent information from cerebrospinal fluid amyloid- β^2 and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015, 138, 772-783. | 7.6 | 200 |
| 1170 | Alzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria. <i>Clinica Chimica Acta</i> , 2015, 449, 3-8. | 1.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1171 | White matter changes in familial Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2015, 278, 211-218. | 6.0 | 30 |
| 1172 | Fluid markers of traumatic brain injury. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 99-102. | 2.2 | 43 |
| 1173 | A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. <i>Neuropsychologia</i> , 2015, 69, 1-8. | 1.6 | 25 |
| 1174 | Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 769-778. | 2.3 | 41 |
| 1175 | A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1240-1247. | 1.9 | 196 |
| 1176 | The Distribution of Apolipoprotein E Genotype Over The Adult Lifespan and in Relation to Country of Birth. <i>American Journal of Epidemiology</i> , 2015, 181, 214-217. | 3.4 | 27 |
| 1177 | Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1316-1328. | 0.8 | 50 |
| 1178 | Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. <i>Nature Medicine</i> , 2015, 21, 217-219. | 30.7 | 68 |
| 1179 | Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190. | 0.8 | 254 |
| 1180 | The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791. | 0.8 | 79 |
| 1181 | Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715. | 7.6 | 109 |
| 1182 | Cerebrospinal fluid tau and amyloid- β_{1-42} in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731. | 7.6 | 152 |
| 1183 | Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596. | 3.1 | 30 |
| 1184 | Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <i>Clinica Chimica Acta</i> , 2015, 449, 9-15. | 1.1 | 66 |
| 1185 | Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015, 11, 1470-1479. | 0.8 | 17 |
| 1186 | APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. <i>Cell Reports</i> , 2015, 11, 689-696. | 6.4 | 158 |
| 1187 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924. | 7.4 | 1,166 |
| 1188 | Laboratory Testing for Lyme Neuroborreliosis. <i>JAMA Neurology</i> , 2015, 72, 125. | 9.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1189 | CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315. | 0.8 | 104 |
| 1190 | Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 550-561. | 3.0 | 126 |
| 1191 | Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 297-309. | 8.7 | 404 |
| 1192 | Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015, 262, 2722-2730. | 3.6 | 39 |
| 1193 | Protective properties of lysozyme on A β -amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015, 83, 122-133. | 4.4 | 58 |
| 1194 | Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015, 85, 1834-1842. | 1.1 | 109 |
| 1195 | Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1175. | 9.0 | 148 |
| 1196 | The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 81-86. | 2.4 | 7 |
| 1197 | Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 40. | 6.2 | 104 |
| 1198 | C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1461-1469. | 0.8 | 117 |
| 1199 | Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249. | 1.1 | 288 |
| 1200 | Neurogranin Levels in Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2015, 72, 1237. | 9.0 | 19 |
| 1201 | Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3373-3385. | 7.6 | 200 |
| 1202 | Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 609, 58-62. | 2.1 | 20 |
| 1203 | A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden. <i>Biological Psychiatry</i> , 2015, 78, 730-736. | 1.3 | 70 |
| 1204 | Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. <i>Brain, Behavior, and Immunity</i> , 2015, 43, 198-204. | 4.1 | 51 |
| 1205 | Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. <i>Journal of Neurotrauma</i> , 2015, 32, 1294-1300. | 3.4 | 99 |
| 1206 | Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1207 | Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69. | 0.8 | 352 |
| 1208 | ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-8. | 2.7 | 35 |
| 1209 | AMYLOID AND TAU BIOMARKERS IN CSF. <i>Journal of prevention of Alzheimer's disease, The</i> , 2015, 2, 1-5. | 2.7 | 5 |
| 1210 | Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. <i>Diving and Hyperbaric Medicine</i> , 2015, 45, 240-3. | 0.5 | 4 |
| 1211 | Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers. <i>PLoS ONE</i> , 2014, 9, e99870. | 2.5 | 30 |
| 1212 | Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 385-394. | 1.3 | 33 |
| 1213 | Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2584-2592. | 3.8 | 26 |
| 1214 | β -site amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces A β 25-X peptides through alternative amyloid precursor protein cleavage. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 75. | 6.2 | 31 |
| 1215 | Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <i>Translational Psychiatry</i> , 2014, 4, e419-e419. | 4.8 | 39 |
| 1216 | Comment on "An antidepressant decreases CSF A β 2 production in healthy individuals and in transgenic AD mice". <i>Science Translational Medicine</i> , 2014, 6, 268le5. | 12.4 | 8 |
| 1217 | Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 297-304. | 1.3 | 82 |
| 1218 | Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543. | 3.7 | 96 |
| 1219 | SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53. | 10.8 | 216 |
| 1220 | Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 549-560. | 2.8 | 99 |
| 1221 | Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282. | 9.0 | 300 |
| 1222 | Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183. | 11.0 | 85 |
| 1223 | Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 476. | 9.0 | 164 |
| 1224 | Tau, S-100 Calcium-Binding Protein B, and Neuron-Specific Enolase as Biomarkers of Concussion. Reply. <i>JAMA Neurology</i> , 2014, 71, 926. | 9.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1225 | Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 877-886. | 2.6 | 26 |
| 1226 | CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953. | 1.1 | 213 |
| 1227 | Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players. <i>JAMA Neurology</i> , 2014, 71, 684. | 9.0 | 336 |
| 1228 | CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014, 269, 87-89. | 2.3 | 51 |
| 1229 | Neurochemical Evidence of Potential Neurotoxicity After Prophylactic Cranial Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 607-614. | 0.8 | 16 |
| 1230 | The amyloid- β degradation pattern in plasma – A possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014, 573, 7-12. | 2.1 | 62 |
| 1231 | The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131. | 0.8 | 250 |
| 1232 | Biomarkers in Amyloid- β Immunotherapy Trials in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2014, 39, 189-201. | 5.4 | 66 |
| 1233 | Cerebrospinal fluid biomarkers in cardiac arrest survivors. <i>Resuscitation</i> , 2014, 85, 227-232. | 3.0 | 25 |
| 1234 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629. | 10.2 | 2,657 |
| 1235 | Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333. | 27.0 | 1,613 |
| 1236 | CSF A β 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. , 2014, 10, 381-392. | | 64 |
| 1237 | Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients. <i>Neuropsychopharmacology</i> , 2014, 39, 2349-2356. | 5.4 | 68 |
| 1238 | CSF A β 1-42 predicts early-onset dementia in Parkinson disease. <i>Neurology</i> , 2014, 82, 1784-1790. | 1.1 | 135 |
| 1239 | Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid- β in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2014, 60, 987-994. | 3.2 | 132 |
| 1240 | The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817. | 0.8 | 163 |
| 1241 | Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ϵ 4 status and cerebrospinal fluid amyloid- β 1-42 levels. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 20. | 6.2 | 48 |
| 1242 | Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. <i>NeuroMolecular Medicine</i> , 2014, 16, 510-516. | 3.4 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1243 | The cerebrospinal fluid “Alzheimer profile” Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713. | 0.8 | 249 |
| 1244 | Automated cerebrospinal fluid cell count “ New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30. | 1.9 | 22 |
| 1245 | The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiology of Aging, 2014, 35, 1318-1324. | 3.1 | 109 |
| 1246 | Imatinib treatment and A β 242 in humans. Alzheimer's and Dementia, 2014, 10, S374-80. | 0.8 | 15 |
| 1247 | Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449. | 4.4 | 105 |
| 1248 | Levels of cerebrospinal fluid β -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 25. | 6.2 | 169 |
| 1249 | Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain, Behavior, and Immunity, 2014, 41, 55-58. | 4.1 | 75 |
| 1250 | Blood “cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Research, 2014, 217, 143-146. | 3.3 | 36 |
| 1251 | Cerebrospinal fluid sphingolipids, β -amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2486-2494. | 3.1 | 57 |
| 1252 | CSF biomarkers for Alzheimer's pathology and the effect size of APOE ϵ 4. Molecular Psychiatry, 2014, 19, 148-149. | 7.9 | 30 |
| 1253 | Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072. | 2.6 | 71 |
| 1254 | Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 335-343. | 1.3 | 32 |
| 1255 | Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S13821. | 1.9 | 82 |
| 1256 | Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726. | 2.6 | 53 |
| 1257 | Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1393-1402. | 2.6 | 26 |
| 1258 | P4-049: IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE. , 2014, 10, P800-P800. | | 0 |
| 1259 | P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511. | | 0 |
| 1260 | P3-103: INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS. , 2014, 10, P666-P666. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1261 | THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2014, 1, 1-22. | 2.7 | 48 |
| 1262 | Plasma tau levels in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 9. | 6.2 | 328 |
| 1263 | Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 2. | 6.2 | 16 |
| 1264 | CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261. | 0.8 | 344 |
| 1265 | Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study. <i>Resuscitation</i> , 2013, 84, 351-356. | 3.0 | 199 |
| 1266 | Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , 2013, 9, 137-140. | 0.8 | 105 |
| 1267 | The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 369-376. | 2.5 | 53 |
| 1268 | Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <i>Journal of Neurology</i> , 2013, 260, 620-626. | 3.6 | 87 |
| 1269 | A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of A β ³⁸ , A β ⁴⁰ , and A β ⁴² in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1021-1032. | 2.6 | 100 |
| 1270 | Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. <i>Brain Injury</i> , 2013, 27, 425-433. | 1.2 | 127 |
| 1271 | Idiopathic normal-pressure hydrocephalus. <i>Neurology</i> , 2013, 80, 1385-1392. | 1.1 | 140 |
| 1272 | Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e76523. | 2.5 | 173 |
| 1273 | Cerebrospinal Fluid Levels of β -Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. <i>Archives of General Psychiatry</i> , 2012, 69, 98. | 12.3 | 554 |
| 1274 | The Neuropathology and Neurobiology of Traumatic Brain Injury. <i>Neuron</i> , 2012, 76, 886-899. | 8.1 | 555 |
| 1275 | Fluid Biomarkers in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006221-a006221. | 6.2 | 159 |
| 1276 | Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. <i>Archives of Neurology</i> , 2012, 69, 1445. | 4.5 | 407 |
| 1277 | Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β ⁴² . <i>Biomarkers in Medicine</i> , 2012, 6, 409-417. | 1.4 | 76 |
| 1278 | Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. <i>PLoS ONE</i> , 2012, 7, e38639. | 2.5 | 73 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1279 | An online nano-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , 2012, 47, 591-603. | 1.6 | 78 |
| 1280 | SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. <i>Journal of Proteomics</i> , 2011, 75, 425-434. | 2.4 | 56 |
| 1281 | The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386. | 0.8 | 354 |
| 1282 | Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans. <i>PLoS ONE</i> , 2011, 6, e28263. | 2.5 | 149 |
| 1283 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 537-546. | 2.6 | 68 |
| 1284 | No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 245-251. | 2.1 | 28 |
| 1285 | Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. <i>NeuroMolecular Medicine</i> , 2011, 13, 151-159. | 3.4 | 104 |
| 1286 | Paving the way for Alzheimer disease drug development. <i>Nature Reviews Neurology</i> , 2011, 7, 65-66. | 10.1 | 7 |
| 1287 | Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1119-1128. | 2.6 | 110 |
| 1288 | Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 120, 185-193. | 7.7 | 268 |
| 1289 | Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010, 1362, 13-22. | 2.2 | 180 |
| 1290 | Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. <i>European Journal of Neurology</i> , 2010, 17, 377-382. | 3.3 | 100 |
| 1291 | Biomarkers in Alzheimer's disease drug development. <i>Nature Medicine</i> , 2010, 16, 1218-1222. | 30.7 | 118 |
| 1292 | Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-11. | 2.0 | 161 |
| 1293 | Evaluation of plasma $A\beta_{40}$ and $A\beta_{42}$ as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 357-367. | 3.1 | 242 |
| 1294 | The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOE ϵ 4, and age of dementia onset. <i>Neurobiology of Aging</i> , 2010, 31, 910-916. | 3.1 | 21 |
| 1295 | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 131-144. | 10.1 | 1,598 |
| 1296 | CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010, 74, 1531-1537. | 1.1 | 182 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1297 | Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. Alzheimer's Research and Therapy, 2010, 2, 8. | 6.2 | 19 |
| 1298 | Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the ϵ 4/ ϵ 2/ ϵ 3 APOE Genotype. Dementia and Geriatric Cognitive Disorders, 2009, 27, 458-464. | 1.5 | 119 |
| 1299 | Low frequency of post-lumbar puncture headache in demented patients. Acta Neurologica Scandinavica, 2009, 88, 221-223. | 2.1 | 74 |
| 1300 | Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585. | 2.8 | 60 |
| 1301 | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413. | 5.3 | 1,803 |
| 1302 | Use of CSF biomarkers in Alzheimer's disease clinical trials. Journal of Nutrition, Health and Aging, 2009, 13, 358-361. | 3.3 | 15 |
| 1303 | Evolution of $A\beta$ 42 and $A\beta$ 40 levels and $A\beta$ 42/ $A\beta$ 40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. Journal of Nutrition, Health and Aging, 2009, 13, 205-208. | 3.3 | 52 |
| 1304 | The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiology of Aging, 2009, 30, 672-681. | 3.1 | 80 |
| 1305 | Transient Inflammation in Neurogenic Regions after Irradiation of the Developing Brain. Radiation Research, 2009, 171, 66-76. | 1.5 | 77 |
| 1306 | CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385. | 7.4 | 1,009 |
| 1307 | Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627. | 10.2 | 542 |
| 1308 | Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7. | 4.5 | 193 |
| 1309 | What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimer's disease?. Aging Health, 2008, 4, 213-215. | 0.3 | 0 |
| 1310 | Prediction of Alzheimer's Disease Using the CSF $A\beta$ 42/ $A\beta$ 40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320. | 1.5 | 248 |
| 1311 | Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2007, 24, 118-124. | 1.5 | 148 |
| 1312 | Characterization of Amyloid β Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry. Journal of Proteome Research, 2007, 6, 4433-4439. | 3.7 | 135 |
| 1313 | Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuroscience Letters, 2007, 419, 18-22. | 2.1 | 169 |
| 1314 | Cystatin C in cerebrospinal fluid and multiple sclerosis. Annals of Neurology, 2007, 62, 193-196. | 5.3 | 31 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1315 | Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. <i>Nature Medicine</i> , 2007, 13, 1359-1362. | 30.7 | 969 |
| 1316 | Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of <i>SOD1</i> genotype. <i>European Journal of Neurology</i> , 2007, 14, 1329-1333. | 3.3 | 118 |
| 1317 | Alzheimer's disease. <i>Lancet</i> , The, 2006, 368, 387-403. | 13.7 | 3,074 |
| 1318 | Determination of β -Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. <i>Journal of Proteome Research</i> , 2006, 5, 1010-1016. | 3.7 | 187 |
| 1319 | Neurochemical aftermath of amateur boxing. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2006, 16, 470-470. | 2.9 | 2 |
| 1320 | Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid- β 1-42 and plasma apolipoprotein levels. <i>Journal of Human Genetics</i> , 2006, 51, 171-179. | 2.3 | 10 |
| 1321 | Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. <i>Lancet Neurology</i> , The, 2006, 5, 228-234. | 10.2 | 1,494 |
| 1322 | Cerebrospinal fluid β -amyloid 1-42 concentration may predict cognitive decline in older women. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 461-464. | 1.9 | 189 |
| 1323 | Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. <i>Neurology</i> , 2006, 67, 1600-1604. | 1.1 | 279 |
| 1324 | Neurochemical Aftermath of Amateur Boxing. <i>Archives of Neurology</i> , 2006, 63, 1277. | 4.5 | 310 |
| 1325 | Analytical performance and clinical utility of the INNOTEST β PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80. | 2.3 | 145 |
| 1326 | The transcobalamin 776C>G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2005, 17, 329-331. | 1.0 | 3 |
| 1327 | Simultaneous Measurement of β -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. <i>Clinical Chemistry</i> , 2005, 51, 336-345. | 3.2 | 400 |
| 1328 | CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 661-672. | 3.1 | 122 |
| 1329 | Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. <i>International Journal of Molecular Medicine</i> , 2005, 16, 1147-9. | 4.0 | 44 |
| 1330 | Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95. | 12.3 | 390 |
| 1331 | CSF biomarkers for mild cognitive impairment. <i>Journal of Internal Medicine</i> , 2004, 256, 224-234. | 6.0 | 138 |
| 1332 | Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. <i>Journal of Internal Medicine</i> , 2004, 256, 240-246. | 6.0 | 4,039 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1333 | Cerebrospinal fluid protein biomarkers for Alzheimer's disease. <i>NeuroRx</i> , 2004, 1, 213-225. | 6.0 | 418 |
| 1334 | Cerebrospinal fluid protein biomarkers for Alzheimer's disease. <i>Neurotherapeutics</i> , 2004, 1, 213-225. | 4.4 | 0 |
| 1335 | CSF markers for incipient Alzheimer's disease. <i>Lancet Neurology</i> , The, 2003, 2, 605-613. | 10.2 | 1,156 |
| 1336 | Lipid analyses of human brain rafts. <i>Journal of Neurochemistry</i> , 2003, 85, 34-34. | 3.9 | 3 |
| 1337 | CSF A β 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. <i>Neurology</i> , 2003, 60, 652-656. | 1.1 | 532 |
| 1338 | CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. <i>Brain Research Bulletin</i> , 2003, 61, 235-242. | 3.0 | 68 |
| 1339 | An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease. <i>Archives of Internal Medicine</i> , 2003, 163, 1524. | 3.8 | 671 |
| 1340 | Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 169-176. | 1.5 | 170 |
| 1341 | Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. <i>Archives of Neurology</i> , 2002, 59, 1267. | 4.5 | 256 |
| 1342 | CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. <i>Neurology</i> , 2002, 59, 627-629. | 1.1 | 227 |
| 1343 | Decreased CSF- β -Amyloid 42 in Alzheimer's Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β -Amyloid Induced by Disparate Mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 112-118. | 1.5 | 125 |
| 1344 | Reply to "MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis". <i>European Journal of Human Genetics</i> , 2002, 10, 579-582. | 2.8 | 8 |
| 1345 | Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001, 297, 187-190. | 2.1 | 401 |
| 1346 | The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264. | 1.5 | 102 |
| 1347 | Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. <i>Journal of Neuroscience Research</i> , 2001, 66, 510-516. | 2.9 | 175 |
| 1348 | Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. <i>Electrophoresis</i> , 2001, 22, 1834-1837. | 2.4 | 34 |
| 1349 | Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. <i>Proteomics</i> , 2001, 1, 444-452. | 2.2 | 112 |
| 1350 | CSF Total tau, A β 42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2001, 24, 087-098. | 4.0 | 232 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1351 | Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2001, 9, 437-444. | 2.8 | 142 |
| 1352 | Evaluation of CSF-tau and CSF-A β 242 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. <i>Archives of Neurology</i> , 2001, 58, 373-9. | 4.5 | 487 |
| 1353 | Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. <i>Neurochemical Research</i> , 2000, 25, 511-517. | 3.3 | 80 |
| 1354 | No association between the β 2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. <i>Journal of Neural Transmission</i> , 2000, 107, 1065-1079. | 2.8 | 101 |
| 1355 | Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. <i>Journal of Neural Transmission</i> , 2000, 107, 1085-1097. | 2.8 | 25 |
| 1356 | CSF levels of tau, β 2-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , 2000, 107, 563-579. | 2.8 | 227 |
| 1357 | Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 199-206. | 2.6 | 183 |
| 1358 | Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. <i>Neuroscience Letters</i> , 2000, 285, 49-52. | 2.1 | 452 |
| 1359 | Standardization of measurement of β 2-amyloid (1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 245-258. | 3.0 | 286 |
| 1360 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2000, 12, 11-20. | 0.7 | 0 |
| 1361 | Cerebrospinal Fluid β 2-Amyloid(1-42) in Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 673. | 4.5 | 594 |
| 1362 | Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. <i>Journal of Clinical Immunology</i> , 1999, 19, 223-230. | 3.8 | 300 |
| 1363 | The Growth-Associated Protein GAP-43 Is Increased in the Hippocampus and in the Cingulate Gyrus in Schizophrenia. <i>Journal of Molecular Neuroscience</i> , 1999, 13, 101-110. | 2.3 | 49 |
| 1364 | Identification of proteins in a human pleural exudate using two-dimensional preparative liquid-phase electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry. <i>Electrophoresis</i> , 1999, 20, 860-865. | 2.4 | 49 |
| 1365 | Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. <i>Electrophoresis</i> , 1999, 20, 431-437. | 2.4 | 89 |
| 1366 | Removal of sodium dodecyl sulfate from protein samples prior to matrix-assisted laser desorption/ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1999, 13, 344-349. | 1.5 | 91 |
| 1367 | Analysis of intact proteins from cerebrospinal fluid by matrix-assisted laser desorption/ionization mass spectrometry after two-dimensional liquid-phase electrophoresis. , 1999, 13, 2450-2455. | | 19 |
| 1368 | Cerebrospinal fluid tau and A β 242 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. <i>Neuroscience Letters</i> , 1999, 273, 5-8. | 2.1 | 239 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1369 | Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998, 19, 379-384. | 3.1 | 80 |
| 1370 | Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1998, 10, 11-23. | 1.0 | 161 |
| 1371 | Combination of the different biological markers for increasing specificity of in vivo Alzheimer's disease testing. <i>Journal of Neural Transmission Supplementum</i> , 1998, 53, 223-235. | 0.5 | 28 |
| 1372 | Decreased Lumbar Cerebrospinal Fluid Levels of Monoamine Metabolites in Vascular Dementia. <i>International Psychogeriatrics</i> , 1996, 8, 425-436. | 1.0 | 21 |
| 1373 | Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. <i>Journal of Neural Transmission</i> , 1996, 103, 603-618. | 2.8 | 172 |
| 1374 | Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid. <i>Molecular and Chemical Neuropathology</i> , 1996, 27, 195-210. | 1.0 | 85 |
| 1375 | The neurochemistry of Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 77-86. | 2.1 | 14 |
| 1376 | Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 185-199. | 2.3 | 84 |
| 1377 | tau protein in cerebrospinal fluid. <i>Molecular and Chemical Neuropathology</i> , 1995, 26, 231-245. | 1.0 | 704 |
| 1378 | Detection of cerebrospinal fluid leakage by isoelectric focusing on polyacrylamide gels with silver staining using the PhastSystem?. <i>Acta Neurochirurgica</i> , 1995, 136, 135-139. | 1.7 | 16 |
| 1379 | Chromogranin A in Cerebrospinal Fluid: A Biochemical Marker for Synaptic Degeneration in Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 306-311. | 1.5 | 24 |
| 1380 | Cerebrospinal Fluid α -Neuronal Thread Protein Comes from Serum by Passage over the Blood-Brain Barrier. <i>Experimental Neurology</i> , 1995, 4, 187-193. | 1.7 | 16 |
| 1381 | Cerebrospinal Fluid Biochemical Markers in Alzheimer's Disease. , 1995, , 13-24. | | 0 |
| 1382 | Neuron specific enolase in cerebrospinal fluid: A biochemical marker for neuronal degeneration in dementia disorders?. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1994, 8, 183-191. | 1.2 | 43 |
| 1383 | Formulas for the quantitation of intrathecal IgG production. <i>Journal of the Neurological Sciences</i> , 1994, 121, 90-96. | 0.6 | 37 |
| 1384 | Ubiquitin in Cerebrospinal Fluid in Alzheimer's Disease and Vascular Dementia. <i>International Psychogeriatrics</i> , 1994, 6, 13-22. | 1.0 | 37 |
| 1385 | Neuropeptidergic and Monoaminergic Function in Suicide Victims. <i>Neuropsychopharmacology</i> , 1994, 11, 265-265. | 5.4 | 0 |
| 1386 | Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1993, 5, 5-15. | 1.2 | 38 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1387 | Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18â€“88 years of age. European Neuropsychopharmacology, 1993, 3, 55-61. | 0.7 | 59 |
| 1388 | Protein Analysis in Cerebrospinal Fluid. European Neurology, 1993, 33, 129-133. | 1.4 | 162 |
| 1389 | Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiology of Aging, 1992, 13, 107-113. | 3.1 | 52 |
| 1390 | Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging: Clinical and Experimental Research, 1992, 4, 301-6. | 0.3 | 14 |
| 1391 | Subcortical symptoms predominate in vascular dementia. International Journal of Geriatric Psychiatry, 1991, 6, 137-145. | 2.7 | 39 |
| 1392 | Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 1991, 6, 147-154. | 2.7 | 47 |
| 1393 | Gangliosides in Cerebrospinal Fluid in 'Probable Alzheimer's Disease'. Archives of Neurology, 1991, 48, 1032-1035. | 4.5 | 75 |
| 1394 | Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurologica Scandinavica, 1990, 81, 323-326. | 2.1 | 148 |
| 1395 | Confusional symptomatology distinguishes early- and late-onset Alzheimer's disease. Aging: Clinical and Experimental Research, 1990, 2, 395-401. | 0.3 | 4 |
| 1396 | Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 1990, 4, 79-86. | 1.3 | 11 |
| 1397 | CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies. , 0, , 285-291. | | 13 |
| 1398 | CSF Markers for Early Alzheimer's Disease. , 0, , 275-283. | | 0 |
| 1399 | Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. , 0, . | | 1 |